{"text_format":"3","workbook":"xlsx","n_sheets":61,"sheets":["Document and Entity Information","BALANCE SHEETS","BALANCE SHEETS (PARENTHETICAL)","STATEMENTS OF OPERATIONS AND CO","STATEMENTS OF CHANGES IN STOCKH","STATEMENTS OF CHANGES IN STOC_2","STATEMENTS OF CASH FLOWS","Pay vs Performance Disclosure","Insider Trading Arrangements","Insider Trading Policies and Pr","Cybersecurity Risk Management, ","Nature of Operations","Risks and Liquidity","Summary of Significant Accounti","Marketable Securities","Fair Value of Financial Instrum","Property and Equipment","Accrued Expenses and Other Curr","Commitments","Segments","Common Stock","Stock-Based Compensation","Income Taxes","Summary of Significant Accoun_2","Summary of Significant Accoun_3","Marketable Securities (Tables)","Fair Value of Financial Instr_2","Property and Equipment (Tables)","Accrued Expenses and Other Cu_2","Commitments (Tables)","Segments (Tables)","Stock-Based Compensation (Table","Income Taxes (Tables)","Risks and Liquidity - Additiona","Summary of Significant Accoun_4","Summary of Significant Accoun_5","Summary of Significant Accoun_6","Summary of Significant Accoun_7","Marketable Securities - Schedul","Marketable Securities - Additio","Fair Value of Financial Instr_3","Property and Equipment - Schedu","Accrued Expenses and Other Cu_3","Commitments - Additional Inform","Commitments - Schedule of Suppl","Commitments - Schedule of Sup_2","Commitments - Schedule of Futur","Segments - Additional Informati","Segments - Schedule of Signific","Common Stock - Additional Infor","Stock-Based Compensation - Addi","Stock-Based Compensation - Sche","Stock-Based Compensation - Summ","Stock-Based Compensation - Su_2","Stock-Based Compensation - Sc_2","Stock-Based Compensation - Su_3","Stock-Based Compensation - Su_4","Income Taxes - Schedule of Defe","Income Taxes - Additional Infor","Income Taxes - Schedule of Reco","Income Taxes - Schedule of Fede"],"cells_cut":1,"read":"whole","date_system":"1900"}

{"sheet":"Document and Entity Information","index":0,"n_rows":43,"n_cols":4,"rows_kept":43,"merged":[[0,0,1,0]]}
["Document and Entity Information - USD ($) $ in Millions","12 Months Ended"]
[null,"Dec. 31, 2024","Mar. 06, 2025","Jun. 30, 2024"]
["Document Document And Entity Information [Abstract]"," "," "," "]
["Document Type","10-K"," "," "]
["Amendment Flag","false"," "," "]
["Document Annual Report","true"," "," "]
["Document Transition Report","false"," "," "]
["Entity File Number","001-39527"," "," "]
["Entity Interactive Data Current","Yes"," "," "]
["Entity Well-known Seasoned Issuer","No"," "," "]
["Entity Voluntary Filers","No"," "," "]
["Title of 12(b) Security","Common Stock, par value $0.0001 per share"," "," "]
["Security Exchange Name","NASDAQ"," "," "]
["Document Period End Date","Dec. 31,  2024"," "," "]
["Document Fiscal Year Focus","2024"," "," "]
["Document Fiscal Period Focus","FY"," "," "]
["Trading Symbol","PRLD"," "," "]
["Entity Registrant Name","PRELUDE THERAPEUTICS INC"," "," "]
["Entity Central Index Key","0001678660"," "," "]
["Entity Current Reporting Status","Yes"," "," "]
["Current Fiscal Year End Date","--12-31"," "," "]
["Entity Filer Category","Non-accelerated Filer"," "," "]
["Entity Small Business","true"," "," "]
["Entity Emerging Growth Company","true"," "," "]
["Entity Shell Company","false"," "," "]
["Entity Ex Transition Period","false"," "," "]
["Entity Incorporation, State or Country Code","DE"," "," "]
["Entity Tax Identification Number","81-1384762"," "," "]
["Entity Address, Address Line One","175 Innovation Boulevard"," "," "]
["Entity Address, City or Town","Wilmington"," "," "]
["Entity Address, State or Province","DE"," "," "]
["Entity Address, Postal Zip Code","19805"," "," "]
["City Area Code","302"," "," "]
["Local Phone Number","467-1280"," "," "]
["Entity Common Stock, Shares Outstanding"," ",{"v":55154634,"d":"55,154,634 "}," "]
["ICFR Auditor Attestation Flag","false"," "," "]
["Document Financial Statement Error Correction [Flag]","false"," "," "]
["Entity Public Float"," "," ",{"v":66.1,"d":"$ 66.1"}]
["Auditor Firm ID","42"," "," "]
["Auditor Name","Ernst & Young LLP"," "," "]
["Auditor Location","Philadelphia, Pennsylvania"," "," "]
["Documents Incorporated by Reference","Portions of the Registrant’s Definitive Proxy Statement (“Proxy Statement”) relating to the 2025 Annual Meeting of Stockholders will be filed with the Commission within 120 days after the end of the Registrant’s 2024 fiscal year pursuant to Regulation 14A and is incorporated by reference into Part III of this Report. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K."," "," "]
["Auditor Opinion [Text Block]","Opinion on the Financial Statements We have audited the accompanying balance sheets of Prelude Therapeutics Incorporated (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles."," "," "]

{"sheet":"BALANCE SHEETS","index":1,"n_rows":33,"n_cols":3,"rows_kept":33}
["BALANCE SHEETS - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Current assets:"," "," "]
["Cash and cash equivalents",{"v":12474,"d":"$ 12,474"},{"v":25291,"d":"$ 25,291"}]
["Marketable securities",{"v":121140,"d":"121,140 "},{"v":207644,"d":"207,644 "}]
["Prepaid expenses and other current assets",{"v":2281,"d":"2,281 "},{"v":2654,"d":"2,654 "}]
["Total current assets",{"v":135895,"d":"135,895 "},{"v":235589,"d":"235,589 "}]
["Restricted cash",{"v":4044,"d":"4,044 "},{"v":4044,"d":"4,044 "}]
["Property and equipment, net",{"v":6767,"d":"6,767 "},{"v":7325,"d":"7,325 "}]
["Right-of-use asset",{"v":28699,"d":"28,699 "},{"v":30412,"d":"30,412 "}]
["Prepaid expenses and other non-current assets",{"v":110,"d":"110 "},{"v":295,"d":"295 "}]
["Total assets",{"v":175515,"d":"175,515 "},{"v":277665,"d":"277,665 "}]
["Current liabilities:"," "," "]
["Accounts payable",{"v":7732,"d":"7,732 "},{"v":4580,"d":"4,580 "}]
["Accrued expenses and other current liabilities",{"v":15209,"d":"15,209 "},{"v":15768,"d":"15,768 "}]
["Operating lease liability",{"v":2492,"d":"2,492 "},{"v":1481,"d":"1,481 "}]
["Finance lease liability",{"v":208,"d":"208 "}," "]
["Total current liabilities",{"v":25641,"d":"25,641 "},{"v":21829,"d":"21,829 "}]
["Other liabilities",{"v":3090,"d":"3,090 "},{"v":3339,"d":"3,339 "}]
["Operating lease liability",{"v":15325,"d":"15,325 "},{"v":15407,"d":"15,407 "}]
["Total liabilities",{"v":44056,"d":"44,056 "},{"v":40575,"d":"40,575 "}]
["Commitments (note 8)"," "," "]
["Stockholders’ equity:"," "," "]
["Additional paid-in capital",{"v":714982,"d":"714,982 "},{"v":693252,"d":"693,252 "}]
["Accumulated other comprehensive income",{"v":35,"d":"35 "},{"v":223,"d":"223 "}]
["Accumulated deficit",{"v":-583563,"d":"(583,563)"},{"v":-456390,"d":"(456,390)"}]
["Total stockholders’ equity",{"v":131459,"d":"131,459 "},{"v":237090,"d":"237,090 "}]
["Total liabilities and stockholders’ equity",{"v":175515,"d":"175,515 "},{"v":277665,"d":"277,665 "}]
["Voting Common Stock"," "," "]
["Stockholders’ equity:"," "," "]
["Common stock",{"v":4,"d":"4 "},{"v":4,"d":"4 "}]
["Non-voting Common Stock"," "," "]
["Stockholders’ equity:"," "," "]
["Common stock",{"v":1,"d":"$ 1"},{"v":1,"d":"$ 1"}]

{"sheet":"BALANCE SHEETS (PARENTHETICAL)","index":2,"n_rows":11,"n_cols":3,"rows_kept":11}
["BALANCE SHEETS (PARENTHETICAL) - $ / shares","Dec. 31, 2024","Dec. 31, 2023"]
["Voting Common Stock"," "," "]
["Common stock, par value",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Common stock, shares authorized",{"v":487149741,"d":"487,149,741 "},{"v":487149741,"d":"487,149,741 "}]
["Common stock, shares, issued",{"v":42298859,"d":"42,298,859 "},{"v":42063995,"d":"42,063,995 "}]
["Common stock, shares, outstanding",{"v":42298859,"d":"42,298,859 "},{"v":42063995,"d":"42,063,995 "}]
["Non-voting Common Stock"," "," "]
["Common stock, par value",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Common stock, shares authorized",{"v":12850259,"d":"12,850,259 "},{"v":12850259,"d":"12,850,259 "}]
["Common stock, shares, issued",{"v":12850259,"d":"12,850,259 "},{"v":12850259,"d":"12,850,259 "}]
["Common stock, shares, outstanding",{"v":12850259,"d":"12,850,259 "},{"v":12850259,"d":"12,850,259 "}]

{"sheet":"STATEMENTS OF OPERATIONS AND CO","index":3,"n_rows":19,"n_cols":3,"rows_kept":19,"merged":[[0,0,1,0],[0,1,0,2]]}
["STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Operating expenses:"," "," "]
["Revenue from license agreement",{"v":7000,"d":"$ 7,000"}," "]
["Research and development",{"v":117995,"d":"117,995 "},{"v":103393,"d":"$ 103,393"}]
["General and administrative",{"v":28719,"d":"28,719 "},{"v":28884,"d":"28,884 "}]
["Total operating expenses",{"v":146714,"d":"146,714 "},{"v":132277,"d":"132,277 "}]
["Loss from operations",{"v":-139714,"d":"(139,714)"},{"v":-132277,"d":"(132,277)"}]
["Other income, net",{"v":12541,"d":"12,541 "},{"v":10445,"d":"10,445 "}]
["Net loss",{"v":-127173,"d":"$ (127,173)"},{"v":-121832,"d":"$ (121,832)"}]
["Per share information:"," "," "]
["Net loss per share of common stock, basic",{"v":-1.68,"d":"$ (1.68)"},{"v":-2.02,"d":"$ (2.02)"}]
["Net loss per share of common stock, diluted",{"v":-1.68,"d":"$ (1.68)"},{"v":-2.02,"d":"$ (2.02)"}]
["Weighted average common shares outstanding, basic",{"v":75805840,"d":"75,805,840 "},{"v":60357052,"d":"60,357,052 "}]
["Weighted average common shares outstanding diluted",{"v":75805840,"d":"75,805,840 "},{"v":60357052,"d":"60,357,052 "}]
["Comprehensive loss"," "," "]
["Net Income (Loss)",{"v":-127173,"d":"$ (127,173)"},{"v":-121832,"d":"$ (121,832)"}]
["Unrealized (loss) gain on marketable securities, net of tax",{"v":-188,"d":"(188)"},{"v":1915,"d":"1,915 "}]
["Comprehensive loss",{"v":-127361,"d":"$ (127,361)"},{"v":-119917,"d":"$ (119,917)"}]

{"sheet":"STATEMENTS OF CHANGES IN STOCKH","index":4,"n_rows":23,"n_cols":7,"rows_kept":23}
["STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands","Total","Common Stock Voting Common Stock","Common Stock Non-voting Common Stock","Additional Paid-in Capital","Accumulated Other Comprehensive Income (Loss)","Accumulated Deficit"]
["Beginning balance at Dec. 31, 2022",{"v":195437,"d":"$ 195,437"},{"v":4,"d":"$ 4"},{"v":1,"d":"$ 1"},{"v":531682,"d":"$ 531,682"},{"v":-1692,"d":"$ (1,692)"},{"v":-334558,"d":"$ (334,558)"}]
["Beginning balance (shares) at Dec. 31, 2022"," ",{"v":36496994,"d":"36,496,994 "},{"v":11402037,"d":"11,402,037 "}," "," "," "]
["Issuance of common stock and prefunded warrants, net of issuance costs of $2.8 million",{"v":135290,"d":"135,290 "}," "," ",{"v":135290,"d":"135,290 "}," "," "]
["Issuance of common stock and prefunded warrants, net of issuance costs of $2.8 million (shares)"," ",{"v":5312978,"d":"5,312,978 "},{"v":1448222,"d":"1,448,222 "}," "," "," "]
["Issuance of common stock upon exercise of stock options & vesting of RSUs",{"v":30,"d":"30 "}," "," ",{"v":30,"d":"30 "}," "," "]
["Issuance of common stock upon exercise of stock options & vesting of RSUs, (shares)"," ",{"v":84166,"d":"84,166 "}," "," "," "," "]
["Issuance of common stock under ESPP",{"v":634,"d":"634 "}," "," ",{"v":634,"d":"634 "}," "," "]
["Issuance of common stock under ESPP, (shares)"," ",{"v":169857,"d":"169,857 "}," "," "," "," "]
["Unrealized gain (loss) on marketable securities, net of tax",{"v":1915,"d":"1,915 "}," "," "," ",{"v":1915,"d":"1,915 "}," "]
["Stock-based compensation expense, net of forfeitures of restricted stock",{"v":25616,"d":"25,616 "}," "," ",{"v":25616,"d":"25,616 "}," "," "]
["Net Income (Loss)",{"v":-121832,"d":"(121,832)"}," "," "," "," ",{"v":-121832,"d":"(121,832)"}]
["Ending balance at Dec. 31, 2023",{"v":237090,"d":"237,090 "},{"v":4,"d":"$ 4"},{"v":1,"d":"$ 1"},{"v":693252,"d":"693,252 "},{"v":223,"d":"223 "},{"v":-456390,"d":"(456,390)"}]
["Ending balance (shares) at Dec. 31, 2023"," ",{"v":42063995,"d":"42,063,995 "},{"v":12850259,"d":"12,850,259 "}," "," "," "]
["Issuance of common stock upon exercise of stock options & vesting of RSUs",{"v":6,"d":"6 "}," "," ",{"v":6,"d":"6 "}," "," "]
["Issuance of common stock upon exercise of stock options & vesting of RSUs, (shares)"," ",{"v":42000,"d":"42,000 "}," "," "," "," "]
["Issuance of common stock under ESPP",{"v":379,"d":"379 "}," "," ",{"v":379,"d":"379 "}," "," "]
["Issuance of common stock under ESPP, (shares)"," ",{"v":192864,"d":"192,864 "}," "," "," "," "]
["Unrealized gain (loss) on marketable securities, net of tax",{"v":-188,"d":"(188)"}," "," "," ",{"v":-188,"d":"(188)"}," "]
["Stock-based compensation expense, net of forfeitures of restricted stock",{"v":21345,"d":"21,345 "}," "," ",{"v":21345,"d":"21,345 "}," "," "]
["Net Income (Loss)",{"v":-127173,"d":"(127,173)"}," "," "," "," ",{"v":-127173,"d":"(127,173)"}]
["Ending balance at Dec. 31, 2024",{"v":131459,"d":"$ 131,459"},{"v":4,"d":"$ 4"},{"v":1,"d":"$ 1"},{"v":714982,"d":"$ 714,982"},{"v":35,"d":"$ 35"},{"v":-583563,"d":"$ (583,563)"}]
["Ending balance (shares) at Dec. 31, 2024"," ",{"v":42298859,"d":"42,298,859 "},{"v":12850259,"d":"12,850,259 "}," "," "," "]

{"sheet":"STATEMENTS OF CHANGES IN STOC_2","index":5,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (PARENTHETICAL) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Issuance costs",{"v":110,"d":"$ 110"},{"v":2800,"d":"$ 2,800"}]
["Shares withheld for employee taxes",{"v":15455,"d":"15,455 "},{"v":3983,"d":"3,983 "}]

{"sheet":"STATEMENTS OF CASH FLOWS","index":6,"n_rows":36,"n_cols":3,"rows_kept":36,"merged":[[0,0,1,0],[0,1,0,2]]}
["STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Cash flows used in operating activities:"," "," "]
["Net loss",{"v":-127173,"d":"$ (127,173)"},{"v":-121832,"d":"$ (121,832)"}]
["Adjustments to reconcile net loss to net cash used in operating activities:"," "," "]
["Depreciation and amortization",{"v":1772,"d":"1,772 "},{"v":1169,"d":"1,169 "}]
["Noncash lease expense",{"v":1591,"d":"1,591 "},{"v":1936,"d":"1,936 "}]
["Stock-based compensation",{"v":21345,"d":"21,345 "},{"v":25616,"d":"25,616 "}]
["Amortization of premium and discount on marketable securities, net",{"v":-4639,"d":"(4,639)"},{"v":-3473,"d":"(3,473)"}]
["Changes in operating assets and liabilities:"," "," "]
["Prepaid expenses and other current assets",{"v":373,"d":"373 "},{"v":-297,"d":"(297)"}]
["Accounts payable",{"v":3305,"d":"3,305 "},{"v":-2270,"d":"(2,270)"}]
["Accrued expenses and other liabilities",{"v":-808,"d":"(808)"},{"v":2522,"d":"2,522 "}]
["Long-term prepaid expenses and other long-term assets",{"v":295,"d":"295 "},{"v":-8810,"d":"(8,810)"}]
["Operating lease liabilities",{"v":1051,"d":"1,051 "},{"v":-1624,"d":"(1,624)"}]
["Net cash used in operating activities",{"v":-102888,"d":"(102,888)"},{"v":-107063,"d":"(107,063)"}]
["Cash flows provided by (used in) investing activities:"," "," "]
["Purchases of marketable securities",{"v":-52694,"d":"(52,694)"},{"v":-221633,"d":"(221,633)"}]
["Proceeds from maturities of marketable securities",{"v":143649,"d":"143,649 "},{"v":190500,"d":"190,500 "}]
["Purchases of property and equipment",{"v":-764,"d":"(764)"},{"v":-3513,"d":"(3,513)"}]
["Net cash provided by (used in) investing activities",{"v":90191,"d":"90,191 "},{"v":-34646,"d":"(34,646)"}]
["Cash flows (used in) provided by financing activities:"," "," "]
["Proceeds from issuance of common stock and pre-funded warrants, net of offering costs"," ",{"v":135731,"d":"135,731 "}]
["Payment of offering costs",{"v":-110,"d":"(110)"},{"v":-2800,"d":"(2,800)"}]
["Proceeds from issuance of common stock in connection with the exercise of stock options",{"v":60,"d":"60 "},{"v":47,"d":"47 "}]
["Proceeds from the issuance of common stock under ESPP",{"v":379,"d":"379 "},{"v":634,"d":"634 "}]
["Payment of withholding taxes related to stock-based compensation to employees",{"v":-54,"d":"(54)"},{"v":-17,"d":"(17)"}]
["Principal payments on finance lease",{"v":-395,"d":"(395)"}," "]
["Net cash (used in) provided by financing activities",{"v":-120,"d":"(120)"},{"v":136395,"d":"136,395 "}]
["Net decrease in cash and cash equivalents",{"v":-12817,"d":"(12,817)"},{"v":-5314,"d":"(5,314)"}]
["Cash, cash equivalents and restricted cash at beginning of year",{"v":29335,"d":"29,335 "},{"v":34649,"d":"34,649 "}]
["Cash, cash equivalents and restricted cash at end of year",{"v":16518,"d":"16,518 "},{"v":29335,"d":"29,335 "}]
["Supplemental disclosures:"," "," "]
["Property and equipment in accounts payable",{"v":10,"d":"10 "},{"v":163,"d":"163 "}]
["Unrealized (loss) gain on marketable securities",{"v":-188,"d":"$ (188)"},{"v":1915,"d":"1,915 "}]
["Offering costs in accrued expenses and other current liabilities"," ",{"v":131,"d":"$ 131"}]

{"sheet":"Pay vs Performance Disclosure","index":7,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Pay vs Performance Disclosure - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Pay vs Performance Disclosure"," "," "]
["Net Income (Loss)",{"v":-127173,"d":"$ (127,173)"},{"v":-121832,"d":"$ (121,832)"}]

{"sheet":"Insider Trading Arrangements","index":8,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Insider Trading Arrangements","3 Months Ended"]
[null,"Dec. 31, 2024"]
["Trading Arrangements, by Individual"," "]
["Rule 10b5-1 Arrangement Adopted","false"]
["Non-Rule 10b5-1 Arrangement Adopted","false"]
["Rule 10b5-1 Arrangement Terminated","false"]
["Non-Rule 10b5-1 Arrangement Terminated","false"]

{"sheet":"Insider Trading Policies and Pr","index":9,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Insider Trading Policies and Procedures","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Insider Trading Policies and Procedures [Line Items]"," "]
["Insider Trading Policies and Procedures Adopted","true"]

{"sheet":"Cybersecurity Risk Management, ","index":10,"n_rows":18,"n_cols":2,"rows_kept":18,"merged":[[0,0,1,0]]}
["Cybersecurity Risk Management, Strategy, and Governance","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Cybersecurity Risk Management, Strategy, and Governance [Line Items]"," "]
["Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]","Item 1C. Cybersecurity Risk Management and Strategy We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. These systems are connected to and/or accessed from the Internet and, as a result, are susceptible to cyber-attacks. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. A material cyber-attack on our systems, or any other third-party partners or vendors and their key operating systems, may interrupt our ability to operate our business , damage our reputation, or result in monetary damages. Prelude has established an Information Security Policy (\"IS Policy\") in order to establish the high-level direction for properly managing the use, privacy, security, retention, and disposal of Prelude’s information and its assets. The IS Policy was prepared using relevant guidance issued and technology standards that are used across various industries. The IS policy applies to all entities who are using Prelude’s equipment and resources, including but not limited to: employees, contractors, temporary workers, any third parties with access to the Prelude's resources, and cloud IT providers. Prelude's Head of Information Technology (\"IT\") also serves as our Information Security Officer and is primarily responsible for implementing and overseeing the IS Policy and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks. Prelude has also established an Incident Response Policy which includes reporting thresholds and follows standardized identification and authentication practices. If an incident is identified, it is documented by Prelude's Head of IT, who in turn, will report the incident to necessary management members. Board Governance and Management Prelude’s Information Security Officer provides updates on information technology risks, controls and procedure, including Prelude’s plans to mitigate cybersecurity risks and respond to data breaches to Prelude's executive leadership team . Our Information Security Officer has over 20 years of experience in information security and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties . The Chief Financial Officer and the Chief Legal Officer report to the Chair of the Audit Committee prompt and timely information regarding any significant cybersecurity incident. The significant incident will be reported to the remaining Audit Committee members, as well as ongoing updates regarding any such incident until it has been addressed. Such incidents, as warranted, will be reviewed by the Board of Directors. The Board of Directors has delegated responsibility for cybersecurity risk oversight to the Audit Committee, which is responsible for (i) regularly reviewing with management significant cybersecurity, privacy, and IT risks or exposures, and the Company’s policies and processes with respect to risk assessment and risk management of the same; (ii) regularly reviewing with management an assessment of the steps management has taken to monitor and control such risks; and (iii) regularly reporting to the full Board of Directors on such matters. The Chair of the Audit Committee has expertise in risk management which includes IT and cybersecurity. Notwithstanding the approach we take to cybersecurity, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on us. See Item 1A. “Risk Factors” for a discussion of cybersecurity risks. "]
["Cybersecurity Risk Management Processes Integrated [Flag]","true"]
["Cybersecurity Risk Management Processes Integrated [Text Block]","Prelude has established an Information Security Policy (\"IS Policy\") in order to establish the high-level direction for properly managing the use, privacy, security, retention, and disposal of Prelude’s information and its assets. The IS Policy was prepared using relevant guidance issued and technology standards that are used across various industries. The IS policy applies to all entities who are using Prelude’s equipment and resources, including but not limited to: employees, contractors, temporary workers, any third parties with access to the Prelude's resources, and cloud IT providers. Prelude's Head of Information Technology (\"IT\") also serves as our Information Security Officer and is primarily responsible for implementing and overseeing the IS Policy and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks. "]
["Cybersecurity Risk Management Third Party Engaged [Flag]","true"]
["Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]","true"]
["Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]","false"]
["Cybersecurity Risk Board of Directors Oversight [Text Block]"," The Board of Directors has delegated responsibility for cybersecurity risk oversight to the Audit Committee, which is responsible for (i) regularly reviewing with management significant cybersecurity, privacy, and IT risks or exposures, and the Company’s policies and processes with respect to risk assessment and risk management of the same; (ii) regularly reviewing with management an assessment of the steps management has taken to monitor and control such risks; and (iii) regularly reporting to the full Board of Directors on such matters. The Chair of the Audit Committee has expertise in risk management which includes IT and cybersecurity."]
["Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"," The Board of Directors has delegated responsibility for cybersecurity risk oversight to the Audit Committee, which is responsible for (i) regularly reviewing with management significant cybersecurity, privacy, and IT risks or exposures, and the Company’s policies and processes with respect to risk assessment and risk management of the same; (ii) regularly reviewing with management an assessment of the steps management has taken to monitor and control such risks; and (iii) regularly reporting to the full Board of Directors on such matters."]
["Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]","Prelude’s Information Security Officer provides updates on information technology risks, controls and procedure, including Prelude’s plans to mitigate cybersecurity risks and respond to data breaches to Prelude's executive leadership team . Our Information Security Officer has over 20 years of experience in information security and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties . The Chief Financial Officer and the Chief Legal Officer report to the Chair of the Audit Committee prompt and timely information regarding any significant cybersecurity incident. The significant incident will be reported to the remaining Audit Committee members, as well as ongoing updates regarding any such incident until it has been addressed."]
["Cybersecurity Risk Role of Management [Text Block]"," The Board of Directors has delegated responsibility for cybersecurity risk oversight to the Audit Committee, which is responsible for (i) regularly reviewing with management significant cybersecurity, privacy, and IT risks or exposures, and the Company’s policies and processes with respect to risk assessment and risk management of the same; (ii) regularly reviewing with management an assessment of the steps management has taken to monitor and control such risks; and (iii) regularly reporting to the full Board of Directors on such matters. The Chair of the Audit Committee has expertise in risk management which includes IT and cybersecurity. Notwithstanding the approach we take to cybersecurity, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on us. See Item 1A. “Risk Factors” for a discussion of cybersecurity risks."]
["Cybersecurity Risk Management Positions or Committees Responsible [Flag]","true"]
["Cybersecurity Risk Management Positions or Committees Responsible [Text Block]","Prelude's Head of Information Technology (\"IT\") also serves as our Information Security Officer and is primarily responsible for implementing and overseeing the IS Policy and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks. "]
["Cybersecurity Risk Management Expertise of Management Responsible [Text Block]","Our Information Security Officer has over 20 years of experience in information security and possesses the requisite education, skills, experience, and industry certifications expected of an individual assigned to these duties"]
["Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]","regularly reviewing with management an assessment of the steps management has taken to monitor and control such risks;"]
["Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]","true"]

{"sheet":"Nature of Operations","index":11,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Nature of Operations","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Organization, Consolidation and Presentation of Financial Statements [Abstract]"," "]
["Nature of Operations","1. Nature of Operations Prelude Therapeutics Incorporated (the “Company”) is a clinical-stage precision oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. Since beginning operations in 2016, the Company has devoted substantially all its efforts to research and development, conducting preclinical and clinical studies, recruiting management and technical staff, administration, and raising capital."]

{"sheet":"Risks and Liquidity","index":12,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Risks and Liquidity","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Risks And Liquidity [Abstract]"," "]
["Risks and Liquidity","2. Risks and Liquidity The Company faces a number of risks common to early-stage companies in the biotechnology industry. Principal among these risks are the uncertainties in the development process, development of the same or similar technological innovations by competitors, protection of proprietary technology, dependence on key personnel, compliance with government regulations and approval requirements, and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company’s research and development will be successfully completed, adequate protection for the Company’s technology will be obtained, any products developed will obtain necessary government regulatory approval, or any approved products will be commercially viable. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. Since its inception, the Company has incurred operating losses and had an accumulated deficit of $ 583.6 million at December 31, 2024. The Company has no product revenue to date and devotes its efforts to research and development. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company believes that its cash, cash equivalents and marketable securities as of December 31, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the filing date of this Annual Report on Form 10-K. To fund its operating expenses and capital expenditure requirements after that date, the Company plans to seek additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, it could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects."]

{"sheet":"Summary of Significant Accounti","index":13,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Summary of Significant Accounting Policies","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Accounting Policies [Abstract]"," "]
["Summary of Significant Accounting Policies",{"$cut":{"chars":18681,"head":"3. Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”). Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. The most significant estimate relates to accrued clinical trial expenses. Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (CODM) is its Chief Executive Officer . The Company views and manages its operations as a single operating segment. See Note 9 (Segments) for further details. Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments, including cash, restricted cash, accounts payable, and accrued expenses, approximate fair value due to the short-term nature of these instruments. Cash, Cash Equivalents and Restricted cash The Company’s cash equivalents include short-term highly liquid investments with an original maturity of 90 days or less when purchased and are carried at fair value in the accompanying balance sheets. Restricted cash comprises a letter of credit for the benefit of the landlord in connection with the Company’s lease facility. See Note 8 (Commitments) for further details. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that total to the amounts shown in the statement of cash flows:\nDecember 31,\n(in thousands) 2024 2023\nCash and cash equivalents $ 12,474 $ 25,291\nRestricted cash 4,044 4,044\nTotal cash, cash equivalents, and restricted cash shown in statement of cash flows $ 16,518 $ 29,335 Marketable Securities The Company’s marketable securities consist of investments in corporate debt securities, United States, or U.S., government debt securities, and agency securities that are classified as available-for-sale. The securities are carried at fair value with the unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss), a component of stockholders’ equity. Realized gains and losses as well as credit losses, if any, on marketable securities are included in the Company’s statements of operations. The Company classifies marketable securities that are available for use in current operations as current assets on the balance sheets. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is recognized using the straight-line method over the estimated useful li"}}]

{"sheet":"Marketable Securities","index":14,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Marketable Securities","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Investments, Debt and Equity Securities [Abstract]"," "]
["Investments","4. Marketable Securities The following is a summary of the Company’s marketable securities as of December 31, 2024 and 2023.\n(in thousands) Amortized Cost Gross unrealized gain Gross unrealized loss Fair Value\nDecember 31, 2024:\nMarketable securities\nCorporate debt securities $ 70,059 $ 44 $ ( 27 ) $ 70,076\nU.S. government securities 51,046 18 — 51,064\nTotal $ 121,105 $ 62 $ ( 27 ) $ 121,140\nDecember 31, 2023:\nMarketable securities\nAgency securities $ 10,431 $ 19 $ — $ 10,450\nCorporate debt securities 67,806 193 ( 20 ) 67,979\nU.S. government securities 129,184 72 ( 41 ) 129,215\nTotal $ 207,421 $ 284 $ ( 61 ) $ 207,644 The Company’s marketable securities generally have contractual maturity dates of 13 months or less. As of December 31, 2024 , the Company had 16 securities with a total fair market value of $ 18.6 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and is primarily related to the change in market interest rates since purchase and believes that it is more likely than not that it will be able to hold its marketable securities to maturity."]

{"sheet":"Fair Value of Financial Instrum","index":15,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Fair Value of Financial Instruments","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Fair Value Disclosures [Abstract]"," "]
["Fair Value of Financial Instruments","5. Fair Value of Financial Instruments Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The Company follows the provisions of ASC Topic 820, Fair Value Measurement, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: • Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. • Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities. • Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The following fair value hierarchy table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis:\nFair value measurement at reporting date using\n(in thousands) Quoted prices Significant Significant\nDecember 31, 2024:\nAssets:\nCash equivalents (Money Market Funds) $ 11,246 $ — $ —\nMarketable securities\nCorporate debt securities — 70,076 —\nU.S. government securities — 51,064 —\nTotal $ 11,246 $ 121,140 $ —\nDecember 31, 2023:\nAssets:\nCash equivalents (Money Market Funds) $ 24,369 $ — $ —\nMarketable securities\nAgency securities 10,450\nCorporate debt securities — 67,979 —\nU.S. government securities — 129,215 —\nTotal $ 24,369 $ 207,644 $ — "]

{"sheet":"Property and Equipment","index":16,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Property and Equipment","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Property, Plant and Equipment [Abstract]"," "]
["Property and Equipment","6. Property and Equipment Property and equipment consisted of the following:\nDecember 31,\n(in thousands) 2024 2023\nLab equipment $ 7,920 $ 6,643\nLeasehold improvements 1,700 1,582\nIT equipment 505 470\nFurniture and fixtures 1,900 1,858\nConstruction in progress — 338\n12,025 10,891\nLess accumulated depreciation ( 5,258 ) ( 3,566 )\nProperty and equipment, net $ 6,767 $ 7,325 "]

{"sheet":"Accrued Expenses and Other Curr","index":17,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Accrued Expenses and Other Current Liabilities","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Payables and Accruals [Abstract]"," "]
["Accrued Expenses and Other Current Liabilities","7. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following:\nDecember 31,\n(in thousands) 2024 2023\nCompensation and related benefits $ 9,022 $ 9,157\nResearch and development 5,416 5,666\nOther 771 945\n$ 15,209 $ 15,768 "]

{"sheet":"Commitments","index":18,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Commitments","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Commitments and Contingencies Disclosure [Abstract]"," "]
["Commitments","8. Commitments Leases The Company leases office and laboratory space in Wilmington, Delaware under a noncancelable lease (the “Chestnut Run Lease”). The premises includes approximately 81,000 rentable square feet and has an initial term of 162 months with 3 five-year extension options and certain expansion rights. Neither the option to extend nor the expansion rights were recognized as part of the Company's measurement of the ROU asset and operating lease liability as of December 31, 2024. Under the terms of the Chestnut Run Lease, the landlord provided an allowance towards the cost of completing tenant improvements for the premises. The Company concluded that the improvements resulting from both the landlord's build-out and the tenant improvements are the landlord's assets for accounting purposes. Costs incurred by the Company related to tenant improvements in excess of the landlord's allowance were treated as prepaid rent and increased the right-of-use asset on the commencement date. The discount rate used to account for the Company’s operating lease under ASC 842 is the Company’s estimated incremental borrowing rate of 15.0 %. The Company's incremental borrowing rate reflects a collateralized borrowing with a similar term and amount as the Chestnut Run Lease. In April 2024, the Company entered into a 12 month finance lease for equipment. Lease cost for the year ended December 31, 2024 was $ 4.4 million, including $ 0.2 million of short-term lease cost. Lease cost for the year ended December 31, 2023 was $ 2.5 million, including $ 0.2 million of short-term lease cost. Supplemental balance sheet and other information related to our operating and finance leases as of December 31, 2024 and December 31, 2023 were as follows:\n(in thousands)\nLeases Classification December 31, 2024 December 31, 2023\nAssets\nOperating Operating lease right-of-use assets $ 28,699 $ 30,412\nFinance Property and equipment, net 523 —\nTotal leased assets $ 29,222 $ 30,412\nLiabilities\nCurrent:\nOperating Current liabilities, operating lease liability $ 2,492 $ 1,481\nFinance Current liabilities, finance lease liability 208 —\nNon-Current:\nOperating Operating lease liability 15,325 15,407\nTotal lease liabilities $ 18,025 $ 16,888\nWeighted-average discount rate\nOperating lease 15.0 % 15.0 %\nFinance lease 10.5 %\nWeighted-average remaining lease term (years)\nOperating lease 12.4 13.5\nFinance lease 0.3 Supplemental cash flow information related to our leases for the twelve months ended December 31, 2024 and 2023 were as follows:\nYear Ended December 31,\n(in thousands) 2024 2023\nCash paid for amounts included in the measurement of lease liabilities:\nOperating cash flows from operating lease $ 1,583 $ 1,928\nOperating cash flows from finance lease 30 —\nFinancing cash flows from finance lease 395 —\nNon-cash transaction\nRight-of-use asset obtained in exchange for lease obligations:\nOperating lease — 16,680\nFinance lease 603 — As of December 31, 2024 future minimum annual lease payments for operating and finance lease are as follows:\n(in thousands) Operating lease Finance lease\n2025 $ 2,708 $ 213\n2026 2,973 -\n2027 3,047 -\n2028 3,124 -\n2029 3,202 -\nThereafter 26,376 -\nTotal undiscounted lease payments 41,430 213\nLess imputed interest ( 23,613 ) ( 5 )\nLease liability $ 17,817 $ 208\nThe Company paid a security deposit in the form of a letter of credit of $ 4.0 million which is included in the accompanying balance sheet as restricted cash as of December 31, 2024 and 2023 . The security deposit may be reduced to $ 0.5 million over time in accordance with the terms of the Chestnut Run Lease. In connection with the Company’s expansion of operations in the State of Delaware, the Company was approved for a grant from the State of Delaware in 2021 that will provide up to $ 2.4 million in reimbursements over three years for the development of lab space and up to $ 3.1 million to increase jobs in Delaware to meet specific targeted levels through 2023 , which was extended to 2026 during the second quarter of 2024. During the third quarter of 2022, the Company was approved for an additional grant from the State of Delaware for the development of lab space in the amount of $ 1.0 million. In 2022, the Company received cash grants of $ 3.4 million from the State of Delaware for the development of lab space. The Company has met the minimum requirements stated in the grant agreement in order to not be required to pay back any portion of the $ 3.4 million disbursed. The Company deferred the recognition of these grant funds as they relate to capitalized costs and has classified them as long-term liabilities in the accompanying balance sheet. The Company recognizes the grant funds in other income over the length of the lease term. Additionally, if the Company leaves the State of Delaware within five years of the disbursement, the Company is required to return an amount equal to the amount of grant funds disbursed on a pro-rated basis. During the year ended December 31, 2024, the Company recognized $ 0.2 million of other income related to this grant. Employment Agreements The Company entered into employment agreements with key personnel providing for compensation and severance in certain circumstances, as defined in the respective employment agreements. 401(k) Defined Contribution Plan The Company sponsors a 401(k) defined‑contribution plan covering all employees. Participants are permitted to contribute up to 100 % of their eligible annual pretax compensation up to an established federal limit on aggregate participant contributions. The Company provides a match with a maximum amount of 3 % of the participant’s compensation. During the years ended December 31, 2024 and 2023 the Company made matching contributions of $ 0.8 million and $ 0.7 million, respectively. License Agreement In May 2024, the Company and Pathos AI, Inc. (\"Pathos\") entered into a license agreement under which the Company granted to Pathos an exclusive, sublicensable, world-wide license to its selective, brain-penetrant PRMT5 inhibitor, PRT811. Under the terms of the license agreement, the Company received a $ 3.0 million upfront, non-refundable payment. The agreement also included a near term $ 4.0 million payment due to the Company upon the earlier of 180 days following the effective date of the license agreement or the execution of a quality agreement between the parties pursuant to which the Company will transfer title to certain quantities of Active Pharmaceutical Ingredient (“API”). In addition, the Company may receive potential developmental milestone payments up to $ 37.0 million, potential sales milestone payments up to $ 100 million and a range of high single-digit to low double-digit royalties on PRT811 global net sales. The Company assessed the license agreement with Pathos in accordance with ASC 606 and concluded that Pathos is a customer. The license agreement with Pathos includes the transfer of the following goods or services: (i) exclusive license to PRT811, (ii) transfer of licensed know-how and materials (i.e. datasets, regulatory and manufacturing documents, etc.), (iii) participation in a Joint Communication Committee (\"JCC\"), and (iv) execution of a quality agreement pursuant to which the Company will transfer title to certain API. The Company evaluated all of the promised goods or services within the contract and determined which goods and services were separate performance obligations. The Company determined that Pathos could not benefit from the license separately from the related know-how and materials, and accordingly, they represent one combined performance obligation. The execution of a quality agreement pursuant to which the Company will transfer title to certain API was identified as a separate performance obligation. The Company also determined the participation in the JCC is immaterial in the context of the license agreement as the Company has no decision-making ability through its participation in the JCC. The transaction price is allocated to the performance obligations based upon their relative standalone selling prices, which were estimated for (i) the exclusive license and know-how and materials at $ 3.0 million using an adjusted market approach and (ii) execution of a quality agreement pursuant to which the Company will transfer title to certain API at $ 4.0 million using a cost plus margin approach. With respect to the accounting principles identified above, each performance obligation will be recognized at a point in time. The Company determined that the performance obligation for the license and transfer of related know-how and materials would be fully satisfied when the license is granted and key know-how and materials are transferred to Pathos as that is the point at which Pathos can fully use and benefit from the license to PRT811. The performance obligation for the execution of a quality agreement pursuant to which the Company will transfer title to certain API will be satisfied when the legal title to the API is transferred. During 2024, the Company satisfied both performance obligations, resulting in $ 7.0 million of revenue recognized in the statement of operations for the year ended December 31, 2024. Research Collaboration Agreement In November 2023, the Company entered into a multi-year, multi-program agreement with AbCellera to jointly discover, develop, and commercialize novel oncology medicines for up to five programs. Under the terms of the agreement, AbCellera will lead manufacturing activities and the Company will lead clinical development and global commercialization, subject to AbCellera’s option to co-promote any resulting commercial products in the United States. If, at any point one party in the collaboration opts-out of future co-development cost sharing, that party will be entitled to a royalty from commercialization of the collaboration target, dependent on the proportion of their co-development contributions compared to the total development costs of a target as defined within the agreement. The Company concluded that the agreement with AbCellera will be accounted for under the scope of ASC 808 as both parties will actively participate in joint operating activities and are exposed to significant risks and rewards. Under ASC 808, certain transactions between collaborative arrangement participants should follow the accounting for revenue under ASC 606 when the collaborative arrangement participant is a customer for a distinct good or service. The Company determined that the co-development arrangement, as defined in its agreement with AbCellera, does not meet the definition of a customer as defined by ASC 606. As a result, these activities will be accounted for as research and development costs. Costs related to the AbCellera collaboration were not material for the years ended December 31, 2024 and 2023. Other Research and Development Arrangements The Company enters into agreements with CROs to assist in the performance of research and development activities. Expenditures to CROs will represent a significant cost in clinical development for the Company."]

{"sheet":"Segments","index":19,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Segments","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Segment Reporting [Abstract]"," "]
["Segments","9. Segments The Company currently operates as one operating business segment focused on developing innovative medicines in areas of high unmet need for cancer patients. The Company's determination that it operates as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, and planning and forecasting for future periods. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the segment based on net loss, which is reported on the statement of operations and comprehensive loss as net loss. The measure of segment assets is reported on the balance sheet as total assets. To-date, the Company has not recognized any revenue from product sales, and the Company does not expect to generate any revenue from the sale of products in the foreseeable future. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and to make decisions about the allocation of resources, along with cash forecast models. The following tables summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:\nYear ended December 31,\n(in thousands) 2024 2023\nRevenue from license agreement $ 7,000 $ —\nOperating expenses:\nResearch and development\nPRT3789 $ 20,173 $ 9,738\nPRT2527 11,594 7,573\nPRT7732 9,195 —\nDiscovery programs 13,856 12,387\nOther 1,346 12,922\nGeneral costs, including personnel related 61,831 60,773\nTotal research and development 117,995 103,393\nGeneral and administrative 28,719 28,884\nTotal operating expenses $ 146,714 $ 132,277\nLoss from operations ( 139,714 ) ( 132,277 )\nOther income, net 12,541 10,445\nNet loss $ ( 127,173 ) $ ( 121,832 )"]

{"sheet":"Common Stock","index":20,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Common Stock","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Equity [Abstract]"," "]
["Common Stock","10. Common Stock The Company has two classes of common stock: “voting common stock” and “non-voting common stock.” The holders of the voting common stock are entitled to one vote for each share of voting common stock held at all meetings of stockholders . Except as otherwise required by law, the holders of non-voting common stock shall not be entitled to vote at any meetings of stockholders (or written actions in lieu of meetings) and the shares of non-voting common stock shall not be included in determining the number of shares voting or entitled to vote on any matter. Unless required by law, there shall be no cumulative voting. Any holder of non-voting common stock may elect to convert each share of non-voting common stock into one fully paid and non-assessable share of voting common stock at any time by providing written notice to the Company; provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 9.99 % of the Company’s common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in the Company’s restated certificate of incorporation. However, this ownership limitation may be increased (not to exceed 19.99 %) or decreased to any other percentage designated by such holder of non-voting common stock upon 61 days’ notice to the Company. Shelf Registration Statements In May 2024, the Company filed a shelf registration statement (the \"2024 Shelf Registration Statement\") with the SEC for the issuance of common stock, preferred stock, debt securities, warrants, subscription rights and units up to an aggregate amount of $ 400 million. The 2024 Shelf Registration statement was declared effective on June 10, 2024. As of December 31, 2024 , there was $ 400.0 million remaining under the 2024 Shelf Registration Statement. Open Market Sales Agreement In March 2023, in connection with filing a prospectus supplement to its 2021 Shelf Registration Statement, the Company entered into an Open Market Sales Agreement (the \"Sales Agreement\") with Jefferies LLC, as the sales agent, pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering amount of up to $ 75.0 million. In November 2024, the 2021 Shelf Registration Statement expired with respect to the shares to be sold under the Sales Agreement. Accordingly, the Company will need to register the $ 75.0 million of common stock that may be issued and sold pursuant to the Sales Agreement on a subsequent registration statement before any future sales are permitted. The Company will pay Jefferies LLC a commission rate of up to 3.0 % of the aggregate gross proceeds from the sale of any shares of common stock pursuant to the Sales Agreement. At December 31, 2024, there was $ 75.0 million remaining under the Sales Agreement. 2023 financings During the second quarter of 2023, the Company sold 6,761,200 shares of its common stock which comprised of (i) 5,312,978 shares of its voting common stock and (ii) 1,448,222 shares of its non-voting common stock at a price of $ 5.75 per share and to certain investors in lieu of common stock, the Company sold pre-funded warrants to purchase 12,895,256 shares of voting common stock at a price of $ 5.7499 per pre-funded warrant, resulting in gross proceeds to the Company of $ 113.0 million. Of the voting common stock issued, 2,264,456 shares were purchased by the Company’s underwriters in connection with a 30-day option at a price of $ 5.75 per share. Offering costs of $ 2.6 million, of which $ 0.3 million were previously paid and deferred, were recorded to additional paid-in capital in the accompanying balance sheets, resulting in net proceeds of $ 110.4 million. During the fourth quarter of 2023, the Company sold in a private placement pre-funded warrants to purchase 7,936,759 shares of voting common stock at a price of $ 3.1499 per pre-funded warrant, resulting in net proceeds of $ 24.8 million after deducting offering costs of $ 0.2 million. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $ 0.0001 per share exercise price of such pre-funded warrant. As of December 31, 2024 , no pre-funded warrants had been exercised. The pre-funded warrants were classified as a component of permanent stockholders’ equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company’s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company did not conduct any financings in 2024."]

{"sheet":"Stock-Based Compensation","index":21,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Stock-Based Compensation","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Share-Based Payment Arrangement [Abstract]"," "]
["Stock-Based Compensation","11. Stock-Based Compensation The Company has two equity incentive plans: the 2016 Equity Incentive Plan, as amended, and the 2020 Equity Incentive Plan. New awards can only be granted under the 2020 Equity Incentive Plan (the “Plan”). The total number of shares initially authorized under the Plan was 4,680,000 , which was increased on January 1, 2021 and will automatically increase on January 1st of each year, continuing for ten years , in an amount equal to five percent of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year. At December 31, 2024 , 5,417,370 shares were available for future grants and on January 1, 2025, 2,757,455 shares were added to the Plan. The Plan provides for the granting of common stock, incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company’s board of directors. The Company’s stock options vest based on the terms in each award agreement, generally over four-year periods with 25 % of options vesting after 1 year and then monthly thereafter, and have a term of ten years . The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations:\nYear Ended\n(in thousands) 2024 2023\nResearch and development $ 12,134 $ 12,626\nGeneral and administrative 9,211 12,990\n$ 21,345 $ 25,616 Stock Options The following table summarizes stock option activity for the Plan in the years indicated:\nNumber Weighted Weighted\nOutstanding at January 1, 2023 9,390,930 $ 12.08 8.31\nGranted 3,238,898 $ 6.68\nExercised ( 26,899 ) $ 1.78\nForfeited ( 704,483 ) $ 12.58\nOutstanding at December 31, 2023 11,898,446 $ 10.60 7.77\nGranted 3,922,800 $ 4.40\nExercised ( 14,955 ) $ 3.98\nForfeited ( 1,593,753 ) $ 9.09\nOutstanding at December 31, 2024 14,212,538 $ 9.07 7.30\nExercisable at December 31, 2024 8,518,940 $ 11.09 6.40 The aggregate intrinsic value of options exercised was $ 20 thousand and $ 0.1 million during the year ended December 31, 2024 and 2023, respectively. At December 31, 2024 , the aggregate intrinsic value of outstanding options and exercisable options was $ 0.1 million and $4 0 thousand, respectively. The following table summarizes information about stock options outstanding and exercisable at December 31, 2024 under the Plan:\nOptions Outstanding Options Exercisable\nRange of Exercise Prices Number Weighted Weighted Number Weighted\n$ 0.31 - $ 4.56 2,991,916 6.29 $ 2.44 2,051,205 $ 1.91\n$ 4.57 - $ 5.43 3,741,327 8.65 4.69 841,091 4.89\n$ 5.44 - $ 11.72 4,088,593 7.82 7.86 2,404,123 8.13\n$ 11.73 - $ 88.98 3,390,702 6.09 21.20 3,222,521 20.75\n14,212,538 8,518,940 The weighted-average grant date fair value of options granted was $ 3.25 and $ 4.87 per share for the years ended December 31, 2024 and 2023 , respectively. The Company recorded stock-based compensation expense of $ 20.8 million and $ 24.6 million for the years ended December 31, 2024 and 2023, respectively, related to stock options. As of December 31, 2024 , the total unrecognized compensation expense related to unvested stock option awards was $ 21.9 million, which the Company expects to recognize over a weighted-average period of 2.04 years. The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:\nYear Ended\n2024 2023\nExpected volatility 84.96 % 83.57 %\nRisk-free interest rate 4.19 % 3.82 %\nExpected life (in years) 6.05 6.02\nExpected dividend yield — — Restricted Stock Awards and Units The Company issues restricted stock awards (“RSA”) to employees that generally vest over a four-year period with 25 % of awards vesting after 1 year and then monthly thereafter. Any unvested shares will be forfeited upon termination of services. The fair value of an RSA is equal to the fair market value price of the Company’s common stock on the date of grant. RSA expense is recorded on a straight-line basis over the vesting period. The following table summarizes activity related to RSA stock-based payment awards:\nNumber of Weighted-\nUnvested balance at January 1, 2023 201,716 $ 2.81\nVested ( 174,708 ) $ 2.74\nUnvested balance at December 31, 2023 27,008 $ 3.26\nVested ( 27,008 ) $ 3.26\nUnvested balance at December 31, 2024 — $ — The Company recorded stock-based compensation expense of $ 0.1 million and $ 0.5 million for the years ended December 31, 2024 and 2023, respectively, related to RSAs. The Company issues restricted stock units (“RSU”) to employees that generally vest over a four-year period with 25 % of awards vesting after 1 year and then quarterly thereafter. Any unvested shares will be forfeited upon termination of services. The following table summarizes activity related to RSU stock-based payment awards:\nNumber of Weighted-\nOutstanding at January 1, 2023 165,000 $ 6.08\nVested ( 61,250 ) $ 5.96\nOutstanding at December 31, 2023 103,750 $ 6.16\nVested ( 42,500 ) $ 6.44\nForfeited ( 5,000 ) $ 18.32\nOutstanding at December 31, 2024 56,250 $ 4.86 The Company recorded stock-based compensation expense of $ 0.3 million for each of the years ended December 31, 2024 and 2023, related to RSUs. At December 31, 2024 the total unrecognized expense related to the RSUs was $ 0.2 million, which the Company expects to recognize over 1.25 years. Employee Stock Purchase Plan The Company has an Employee Stock Purchase Plan (the “ESPP”), which as of December 31, 2024 had 1,975,570 shares of common stock reserved for future issuance. The Company issued 192,864 shares under the ESPP in 2024 . The number of shares of the Company’s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January 1st of each year and continuing for ten years beginning in 2021, in an amount equal to one percent of the total number of shares of all classes of the Company’s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year. As such, on January 1, 2025, 551,491 shares were added to the ESPP. Under the ESPP, eligible employees can purchase the Company’s common stock through accumulated payroll deductions at such times as are established by the Company's compensation committee. Eligible employees may purchase the Company’s common stock at 85 % of the lower of the fair market value of the Company’s common stock on the first day of the offering period or on the last day of the offering period. Eligible employees may contribute up to 15 % of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $ 25,000 worth of the Company’s common stock for each calendar year in which such right is outstanding. The ESPP is considered compensatory under the FASB stock compensation rules. Accordingly, share-based compensation expense is determined based on the option’s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of $ 0.2 million and $ 0.3 million for the years ended December 31, 2024 and 2023 , respectively, related to the ESPP."]

{"sheet":"Income Taxes","index":22,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Income Taxes","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Income Tax Disclosure [Abstract]"," "]
["Income Taxes","12. Income Taxes The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:\nDecember 31,\n(in thousands) 2024 2023\nDeferred tax assets:\nNet operating loss carryforwards $ 81,520 $ 71,963\nResearch and development credits 23,668 20,555\nResearch and development capitalization 59,341 39,867\nStock-based compensation 15,312 12,990\nAccrued expense 2,783 2,539\nLease liabilities 5,033 4,715\nGross deferred tax assets 187,657 152,629\nLess: valuation allowance ( 182,642 ) ( 147,616 )\nTotal deferred tax asset 5,015 5,013\nDeferred tax liability\nRight-of-use assets ( 4,595 ) ( 4,641 )\nDepreciation ( 420 ) ( 372 )\nTotal deferred tax liabilities ( 5,015 ) ( 5,013 )\nNet deferred tax assets $ — $ — The deferred tax assets as of December 31, 2024 and 2023, includes capitalized research and development expenses of $ 59.3 million and $ 39.9 million, respectively. The Tax Cuts and Jobs Act passed in 2017 included a provision which requires taxpayers to capitalize and amortize U.S. based research development expenses over a period of five years and non-U.S. based research and development expenses over a period of 15 years effective for tax years beginning after December 31, 2021. In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company’s net deferred tax assets as of December 31, 2024 and December 31, 2023 . The valuation allowance increased by $ 35.0 million and $ 36.6 million during the years ended December 31, 2024 and 2023, respectively. A reconciliation of the federal income tax rate to the Company’s effective tax rate is as follows:\nYear ended\n2024 2023\nFederal tax benefit at statutory rate ( 21.0 )% ( 21.0 )%\nState tax, net of federal benefit ( 6.6 ) ( 6.6 )\nPermanent differences 1.0 1.1\nResearch and development ( 2.4 ) ( 4.4 )\nChange in valuation allowance 27.5 30.0\nShare-based compensation 1.5 0.9\nOther - -\n0 % 0 % The following table summarizes carryforwards of federal and state net operating losses (“NOL”) and research tax credits:\nDecember 31,\n(in thousands) 2024 2023\nNOL carryforwards - Federal $ 292,193 $ 257,976\nNOL carryforwards - State 293,621 259,051\nResearch tax credits - Federal 23,634 20,521\nResearch tax credits - State 43 43 The NOL carryforwards begin expiring in 2036 for federal and Delaware state income tax purposes, however; all federal, Delaware state, and Kansas state NOL carryforwards generated subsequent to January 1, 2018, are able to be carried forward indefinitely. The NOL carryforwards begin expiring in 2037 and 2042 for Tennessee and Massachusetts, respectively. As of December 31, 2024 , the Company also had federal and Delaware research and development tax credit carryforwards of $ 23.6 million and $ 43 thousand, respectively, that will begin to expire in 2039 and 2031 , respectively, unless previously utilized. The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception. Delaware state NOLs may also be limited. As of December 31, 2024 , the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statement of operations. Due to NOL and tax credit carry-forwards that remain unutilized, income tax returns for all tax years remain subject to examination by the taxing jurisdictions. The NOL carryforwards remain subject to review until utilized."]

{"sheet":"Summary of Significant Accoun_2","index":23,"n_rows":20,"n_cols":2,"rows_kept":20,"merged":[[0,0,1,0]]}
["Summary of Significant Accounting Policies (Policies)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Accounting Policies [Abstract]"," "]
["Basis of presentation","Basis of Presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”)."]
["Use of estimates","Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. The most significant estimate relates to accrued clinical trial expenses."]
["Concentration of Credit Risk","Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships."]
["Segment Information","Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (CODM) is its Chief Executive Officer . The Company views and manages its operations as a single operating segment. See Note 9 (Segments) for further details."]
["Fair Value of Financial Instruments","Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments, including cash, restricted cash, accounts payable, and accrued expenses, approximate fair value due to the short-term nature of these instruments."]
["Cash, Cash Equivalents and Restricted Cash","Cash, Cash Equivalents and Restricted cash The Company’s cash equivalents include short-term highly liquid investments with an original maturity of 90 days or less when purchased and are carried at fair value in the accompanying balance sheets. Restricted cash comprises a letter of credit for the benefit of the landlord in connection with the Company’s lease facility. See Note 8 (Commitments) for further details. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that total to the amounts shown in the statement of cash flows:\nDecember 31,\n(in thousands) 2024 2023\nCash and cash equivalents $ 12,474 $ 25,291\nRestricted cash 4,044 4,044\nTotal cash, cash equivalents, and restricted cash shown in statement of cash flows $ 16,518 $ 29,335 "]
["Marketable Securities","Marketable Securities The Company’s marketable securities consist of investments in corporate debt securities, United States, or U.S., government debt securities, and agency securities that are classified as available-for-sale. The securities are carried at fair value with the unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss), a component of stockholders’ equity. Realized gains and losses as well as credit losses, if any, on marketable securities are included in the Company’s statements of operations. The Company classifies marketable securities that are available for use in current operations as current assets on the balance sheets."]
["Property and Equipment","Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset, ranging from 5 - 7 years as follows:\nFixed Asset Type Estimated useful life\nLab equipment 5 years\nIT equipment 5 years\nFurniture and fixtures 7 years Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or the remaining lease term. Expenditures for repairs and maintenance of assets are charged to expense as incurred, while major betterments are capitalized. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in the statements of operations. The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows."]
["Leases","Leases The Company accounts for leases in accordance with ASC Topic 842, Leases. The Company's lease for office and laboratory space located in Wilmington, DE is classified as an operating lease. The lease results in an operating right-of-use (ROU) asset, a current operating lease liability, and a non-current operating lease liability in the balance sheet and has a remaining lease term of approximately 12 years . The Company has a finance lease for a piece of equipment which is included in the balance sheet in property and equipment, net, and as a finance lease liability with a remaining term of 4 months . Leases with a term of 12 months or less are considered short-term and a ROU asset and lease obligation are not recognized. ROU assets represent the right to use an underlying asset for the lease term and the lease liabilities represent an obligation to make lease payments arising from the lease, measured at the present value of the lease payments not yet paid discounted using the discount rate for the lease established at the lease commencement date. The operating lease ROU asset also includes any prepaid lease payments made. Lease expense is recognized over the expected lease term on a straight-line basis. "]
["Comprehensive Loss","Comprehensive loss Comprehensive loss includes net loss and certain changes in stockholders’ equity that are excluded from net loss. The Company’s comprehensive loss for the years ended December 31, 2024 and 2023 comprised net loss and unrealized gain or loss on marketable securities. "]
["Revenue Recognition","Revenue Recognition The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers (\"ASC 606\") . Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company's revenue recognition analysis consists of the following steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations; and (v) recognition of revenue as it satisfies each performance obligation. The Company evaluates all promised goods and services within a customer contract and determines which goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. The transaction price is determined based on the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company recognizes a liability when the Company has received payment but has not yet satisfied the related performance obligations."]
["Stock-Based Compensation","Stock-Based Compensation The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. Estimating the fair value of share-based awards requires the input of subjective assumptions, including, for stock options, the expected life of the options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of share-based awards represent management’s estimate and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. The expected life of the stock options is estimated using the “simplified method”, as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, the Company uses its own historical volatility along with comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option."]
["Grant Income and Research and Development Tax Credits","Grant Income and Research and Development Tax Credits The Company recognizes grants related to income and Delaware research and development tax credits in other income, net in the statements of operations when the necessary qualifying conditions, as stated in the agreements, are met and all contingencies have been resolved. For the years ended December 31, 2024 and 2023 , the Company recorded other income related to these items of $ 2.5 million and $ 1.5 million, respectively. The Company recognizes grants related to assets as deferred income w hich is included in the balance sheet as other liabilities . The deferred income is then recognized as grant income over the useful life of the related assets."]
["Research and Development","Research and Development Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits of employees, and other operational costs related to the Company’s research and development activities, including allocated facility-related expenses and external costs of outside vendors, such as clinical research organizations and clinical manufacturing organizations, and other direct and indirect costs. Management makes estimates of the Company’s accrued research and development expenses as of each balance sheet date in the Company’s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed."]
["Income taxes","Income Taxes Income taxes are accounted for under the asset-and-liability method as required by ASC Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income. ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes , (“ASC 740-10”) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50 % likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company’s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as a component of income tax expense."]
["Net Loss Per Share","Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period, including pre-funded warrants to purchase shares of common stock. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards, as these instruments are considered contingently issuable shares until they vest, or restricted stock units. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise of securities, such as stock options, and the effect from unvested restricted stock awards and restricted stock units which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company’s unvested restricted stock awards entitle the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock awards have no obligation to fund losses. The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:\nDecember 31,\n2024 2023\nUnvested restricted stock awards — 27,008\nUnvested restricted stock units 56,250 103,750\nStock options 14,212,538 11,898,446\n14,268,788 12,029,204 Amounts in the above table reflect the common stock equivalents."]
["Recently Issued Accounting Pronouncements","Recently Issued Accounting Pronouncements Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. The Company will remain an emerging growth company until the earliest of (i) the last day of the Company's first fiscal year (a) in which the Company has total annual gross revenues of at least $ 1.235 billion, or (b) in which the Company is deemed to be a large accelerated filer, which means the market value of the Company's common stock that is held by non-affiliates exceeds $ 700.0 million as of the prior June 30, (ii) the date on which the Company has issued more than $ 1.0 billion in non-convertible debt securities during the prior three-year period or (iii) December 31, 2025. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Accounting guidance not yet adopted In December 2023, the FASB issued ASU Update No. 2023-09, Income Taxes - Improvements to Income Tax Disclosures . ASU 2023-09 requires enhanced income tax disclosures related to the rate reconciliation and income taxes paid information. For public business entities, the amendments in this Update are effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company is currently evaluating the impact of this standard but does not expect that it will have a material impact on the financial statements and related disclosures. In November 2024, the FASB issued ASU Update No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. ASU 2024-03 requires disclosure, in the notes to the financial statements, of specified information about certain costs and expenses. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this standard but does not expect that it will have a material impact on the financial statements and related disclosures."]

{"sheet":"Summary of Significant Accoun_3","index":24,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Summary of Significant Accounting Policies (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Accounting Policies [Abstract]"," "]
["Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash","The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that total to the amounts shown in the statement of cash flows:\nDecember 31,\n(in thousands) 2024 2023\nCash and cash equivalents $ 12,474 $ 25,291\nRestricted cash 4,044 4,044\nTotal cash, cash equivalents, and restricted cash shown in statement of cash flows $ 16,518 $ 29,335 "]
["Schedule of Property Plant and Equipment Useful Life","Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset, ranging from 5 - 7 years as follows:\nFixed Asset Type Estimated useful life\nLab equipment 5 years\nIT equipment 5 years\nFurniture and fixtures 7 years"]
["Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding","The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:\nDecember 31,\n2024 2023\nUnvested restricted stock awards — 27,008\nUnvested restricted stock units 56,250 103,750\nStock options 14,212,538 11,898,446\n14,268,788 12,029,204 "]

{"sheet":"Marketable Securities (Tables)","index":25,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Marketable Securities (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Investments, Debt and Equity Securities [Abstract]"," "]
["Schedule of Marketable Securities","The following is a summary of the Company’s marketable securities as of December 31, 2024 and 2023.\n(in thousands) Amortized Cost Gross unrealized gain Gross unrealized loss Fair Value\nDecember 31, 2024:\nMarketable securities\nCorporate debt securities $ 70,059 $ 44 $ ( 27 ) $ 70,076\nU.S. government securities 51,046 18 — 51,064\nTotal $ 121,105 $ 62 $ ( 27 ) $ 121,140\nDecember 31, 2023:\nMarketable securities\nAgency securities $ 10,431 $ 19 $ — $ 10,450\nCorporate debt securities 67,806 193 ( 20 ) 67,979\nU.S. government securities 129,184 72 ( 41 ) 129,215\nTotal $ 207,421 $ 284 $ ( 61 ) $ 207,644 "]

{"sheet":"Fair Value of Financial Instr_2","index":26,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Fair Value of Financial Instruments (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Fair Value Disclosures [Abstract]"," "]
["Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis","The following fair value hierarchy table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis:\nFair value measurement at reporting date using\n(in thousands) Quoted prices Significant Significant\nDecember 31, 2024:\nAssets:\nCash equivalents (Money Market Funds) $ 11,246 $ — $ —\nMarketable securities\nCorporate debt securities — 70,076 —\nU.S. government securities — 51,064 —\nTotal $ 11,246 $ 121,140 $ —\nDecember 31, 2023:\nAssets:\nCash equivalents (Money Market Funds) $ 24,369 $ — $ —\nMarketable securities\nAgency securities 10,450\nCorporate debt securities — 67,979 —\nU.S. government securities — 129,215 —\nTotal $ 24,369 $ 207,644 $ — "]

{"sheet":"Property and Equipment (Tables)","index":27,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Property and Equipment (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Property, Plant and Equipment [Abstract]"," "]
["Schedule of Property and Equipment","Property and equipment consisted of the following:\nDecember 31,\n(in thousands) 2024 2023\nLab equipment $ 7,920 $ 6,643\nLeasehold improvements 1,700 1,582\nIT equipment 505 470\nFurniture and fixtures 1,900 1,858\nConstruction in progress — 338\n12,025 10,891\nLess accumulated depreciation ( 5,258 ) ( 3,566 )\nProperty and equipment, net $ 6,767 $ 7,325 "]

{"sheet":"Accrued Expenses and Other Cu_2","index":28,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Accrued Expenses and Other Current Liabilities (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Payables and Accruals [Abstract]"," "]
["Summary of Accrued Expenses and Other Current Liabilities","Accrued expenses and other current liabilities consisted of the following:\nDecember 31,\n(in thousands) 2024 2023\nCompensation and related benefits $ 9,022 $ 9,157\nResearch and development 5,416 5,666\nOther 771 945\n$ 15,209 $ 15,768 "]

{"sheet":"Commitments (Tables)","index":29,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Commitments (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Schedule of Supplemental Balance Sheet and Other Information related to Operating and Finance Leases","Supplemental balance sheet and other information related to our operating and finance leases as of December 31, 2024 and December 31, 2023 were as follows:\n(in thousands)\nLeases Classification December 31, 2024 December 31, 2023\nAssets\nOperating Operating lease right-of-use assets $ 28,699 $ 30,412\nFinance Property and equipment, net 523 —\nTotal leased assets $ 29,222 $ 30,412\nLiabilities\nCurrent:\nOperating Current liabilities, operating lease liability $ 2,492 $ 1,481\nFinance Current liabilities, finance lease liability 208 —\nNon-Current:\nOperating Operating lease liability 15,325 15,407\nTotal lease liabilities $ 18,025 $ 16,888\nWeighted-average discount rate\nOperating lease 15.0 % 15.0 %\nFinance lease 10.5 %\nWeighted-average remaining lease term (years)\nOperating lease 12.4 13.5\nFinance lease 0.3 "]
["Schedule of Supplemental Cash Flow Information related to leases","Supplemental cash flow information related to our leases for the twelve months ended December 31, 2024 and 2023 were as follows:\nYear Ended December 31,\n(in thousands) 2024 2023\nCash paid for amounts included in the measurement of lease liabilities:\nOperating cash flows from operating lease $ 1,583 $ 1,928\nOperating cash flows from finance lease 30 —\nFinancing cash flows from finance lease 395 —\nNon-cash transaction\nRight-of-use asset obtained in exchange for lease obligations:\nOperating lease — 16,680\nFinance lease 603 — "]
["Chestnut Run Lease"," "]
["Schedule of Future Minimum Annual Lease Payments Under Operating and Finance Lease","(in thousands) Operating lease Finance lease\n2025 $ 2,708 $ 213\n2026 2,973 -\n2027 3,047 -\n2028 3,124 -\n2029 3,202 -\nThereafter 26,376 -\nTotal undiscounted lease payments 41,430 213\nLess imputed interest ( 23,613 ) ( 5 )\nLease liability $ 17,817 $ 208"]

{"sheet":"Segments (Tables)","index":30,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Segments (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Segment Reporting [Abstract]"," "]
["Schedule of Significant Expense Categories Reviewed by CODM","The following tables summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:\nYear ended December 31,\n(in thousands) 2024 2023\nRevenue from license agreement $ 7,000 $ —\nOperating expenses:\nResearch and development\nPRT3789 $ 20,173 $ 9,738\nPRT2527 11,594 7,573\nPRT7732 9,195 —\nDiscovery programs 13,856 12,387\nOther 1,346 12,922\nGeneral costs, including personnel related 61,831 60,773\nTotal research and development 117,995 103,393\nGeneral and administrative 28,719 28,884\nTotal operating expenses $ 146,714 $ 132,277\nLoss from operations ( 139,714 ) ( 132,277 )\nOther income, net 12,541 10,445\nNet loss $ ( 127,173 ) $ ( 121,832 )"]

{"sheet":"Stock-Based Compensation (Table","index":31,"n_rows":9,"n_cols":2,"rows_kept":9,"merged":[[0,0,1,0]]}
["Stock-Based Compensation (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Share-Based Payment Arrangement [Abstract]"," "]
["Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations","The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations:\nYear Ended\n(in thousands) 2024 2023\nResearch and development $ 12,134 $ 12,626\nGeneral and administrative 9,211 12,990\n$ 21,345 $ 25,616 "]
["Summary of Stock Option Activity","The following table summarizes stock option activity for the Plan in the years indicated:\nNumber Weighted Weighted\nOutstanding at January 1, 2023 9,390,930 $ 12.08 8.31\nGranted 3,238,898 $ 6.68\nExercised ( 26,899 ) $ 1.78\nForfeited ( 704,483 ) $ 12.58\nOutstanding at December 31, 2023 11,898,446 $ 10.60 7.77\nGranted 3,922,800 $ 4.40\nExercised ( 14,955 ) $ 3.98\nForfeited ( 1,593,753 ) $ 9.09\nOutstanding at December 31, 2024 14,212,538 $ 9.07 7.30\nExercisable at December 31, 2024 8,518,940 $ 11.09 6.40 "]
["Summary of Information about Stock Options Outstanding and Exercisable","The following table summarizes information about stock options outstanding and exercisable at December 31, 2024 under the Plan:\nOptions Outstanding Options Exercisable\nRange of Exercise Prices Number Weighted Weighted Number Weighted\n$ 0.31 - $ 4.56 2,991,916 6.29 $ 2.44 2,051,205 $ 1.91\n$ 4.57 - $ 5.43 3,741,327 8.65 4.69 841,091 4.89\n$ 5.44 - $ 11.72 4,088,593 7.82 7.86 2,404,123 8.13\n$ 11.73 - $ 88.98 3,390,702 6.09 21.20 3,222,521 20.75\n14,212,538 8,518,940 "]
["Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions","The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:\nYear Ended\n2024 2023\nExpected volatility 84.96 % 83.57 %\nRisk-free interest rate 4.19 % 3.82 %\nExpected life (in years) 6.05 6.02\nExpected dividend yield — — "]
["Summary of Activity related to RSA Stock-Based Payment Awards","The following table summarizes activity related to RSA stock-based payment awards:\nNumber of Weighted-\nUnvested balance at January 1, 2023 201,716 $ 2.81\nVested ( 174,708 ) $ 2.74\nUnvested balance at December 31, 2023 27,008 $ 3.26\nVested ( 27,008 ) $ 3.26\nUnvested balance at December 31, 2024 — $ — "]
["Summary of Activity related to RSU Stock-Based Payment Awards","The following table summarizes activity related to RSU stock-based payment awards:\nNumber of Weighted-\nOutstanding at January 1, 2023 165,000 $ 6.08\nVested ( 61,250 ) $ 5.96\nOutstanding at December 31, 2023 103,750 $ 6.16\nVested ( 42,500 ) $ 6.44\nForfeited ( 5,000 ) $ 18.32\nOutstanding at December 31, 2024 56,250 $ 4.86 "]

{"sheet":"Income Taxes (Tables)","index":32,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Income Taxes (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Income Tax Disclosure [Abstract]"," "]
["Schedule of Deferred Tax Assets and Liabilities","The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:\nDecember 31,\n(in thousands) 2024 2023\nDeferred tax assets:\nNet operating loss carryforwards $ 81,520 $ 71,963\nResearch and development credits 23,668 20,555\nResearch and development capitalization 59,341 39,867\nStock-based compensation 15,312 12,990\nAccrued expense 2,783 2,539\nLease liabilities 5,033 4,715\nGross deferred tax assets 187,657 152,629\nLess: valuation allowance ( 182,642 ) ( 147,616 )\nTotal deferred tax asset 5,015 5,013\nDeferred tax liability\nRight-of-use assets ( 4,595 ) ( 4,641 )\nDepreciation ( 420 ) ( 372 )\nTotal deferred tax liabilities ( 5,015 ) ( 5,013 )\nNet deferred tax assets $ — $ — "]
["Schedule of Reconciliation of the Federal Income tax Rate to Effective Tax Rate","A reconciliation of the federal income tax rate to the Company’s effective tax rate is as follows:\nYear ended\n2024 2023\nFederal tax benefit at statutory rate ( 21.0 )% ( 21.0 )%\nState tax, net of federal benefit ( 6.6 ) ( 6.6 )\nPermanent differences 1.0 1.1\nResearch and development ( 2.4 ) ( 4.4 )\nChange in valuation allowance 27.5 30.0\nShare-based compensation 1.5 0.9\nOther - -\n0 % 0 %"]
["Schedule of Federal and State Net Operating Losses and Research Tax Credits","The following table summarizes carryforwards of federal and state net operating losses (“NOL”) and research tax credits:\nDecember 31,\n(in thousands) 2024 2023\nNOL carryforwards - Federal $ 292,193 $ 257,976\nNOL carryforwards - State 293,621 259,051\nResearch tax credits - Federal 23,634 20,521\nResearch tax credits - State 43 43 "]

{"sheet":"Risks and Liquidity - Additiona","index":33,"n_rows":3,"n_cols":3,"rows_kept":3}
["Risks and Liquidity - Additional Information (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Risks And Liquidity [Abstract]"," "," "]
["Accumulated deficit",{"v":-583563,"d":"$ (583,563)"},{"v":-456390,"d":"$ (456,390)"}]

{"sheet":"Summary of Significant Accoun_4","index":34,"n_rows":5,"n_cols":3,"rows_kept":5}
["Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Accounting Policies [Abstract]"," "," "]
["Cash and cash equivalents",{"v":12474,"d":"$ 12,474"},{"v":25291,"d":"$ 25,291"}]
["Restricted cash",{"v":4044,"d":"4,044 "},{"v":4044,"d":"4,044 "}]
["Total cash, cash equivalents, and restricted cash shown in statement of cash flows",{"v":16518,"d":"$ 16,518"},{"v":29335,"d":"$ 29,335"}]

{"sheet":"Summary of Significant Accoun_5","index":35,"n_rows":28,"n_cols":3,"rows_kept":28,"merged":[[0,0,1,0],[0,1,0,2]]}
["Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024 USD ($) Segment","Dec. 31, 2023 USD ($)"]
["Summary of Significant Accounting Policies [Line Items]"," "," "]
["Segment reporting, expense information used by codm, description","Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (CODM) is its Chief Executive Officer."," "]
["Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]","us-gaap:SegmentReportingExpenseInformationUsedByCodmConsolidatedMember"," "]
["Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]","srt:ChiefExecutiveOfficerMember"," "]
["Number of operating segments | Segment",{"v":1,"d":"1 "}," "]
["Other income",{"v":12541,"d":"$ 12,541"},{"v":10445,"d":"$ 10,445"}]
["Remaining lease term","12 years"," "]
["Lessee finance lease description","The Company has a finance lease for a piece of equipment which is included in the balance sheet in property and equipment, net, and as a finance lease liability with a remaining term of 4 months."," "]
["Lessee, finance lease, remaining lease term","4 months"," "]
["Research and Development Tax Credits"," "," "]
["Summary of Significant Accounting Policies [Line Items]"," "," "]
["Other income",{"v":2500,"d":"$ 2,500"},{"v":1500,"d":"$ 1,500"}]
["Minimum"," "," "]
["Summary of Significant Accounting Policies [Line Items]"," "," "]
["Property, plant and equipment, useful life","5 years"," "]
["Property, Plant and Equipment, Depreciation Method [Extensible Enumeration]","us-gaap:UsefulLifeTermOfLeaseMember"," "]
["Maximum"," "," "]
["Summary of Significant Accounting Policies [Line Items]"," "," "]
["Property, plant and equipment, useful life","7 years"," "]
["Property, Plant and Equipment, Depreciation Method [Extensible Enumeration]","us-gaap:UsefulLifeTermOfLeaseMember"," "]
["Percentage of tax benefit recognized upon settlement",{"v":0.5,"d":"50%"}," "]
["Emerging growth revenue",{"v":1235000,"d":"$ 1,235,000"}," "]
["Common stock held by non-affiliates",{"v":700000,"d":"700,000 "}," "]
["Maximum | Non-Convertible Debt Securities [Member]"," "," "]
["Summary of Significant Accounting Policies [Line Items]"," "," "]
["Emerging growth debt",{"v":1000000,"d":"$ 1,000,000"}," "]

{"sheet":"Summary of Significant Accoun_6","index":36,"n_rows":10,"n_cols":2,"rows_kept":10}
["Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Useful Life (Details)","Dec. 31, 2024"]
["Lab equipment"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Property, plant and equipment, useful life","5 years"]
["IT equipment"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Property, plant and equipment, useful life","5 years"]
["Furniture and fixtures"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Property, plant and equipment, useful life","7 years"]

{"sheet":"Summary of Significant Accoun_7","index":37,"n_rows":13,"n_cols":3,"rows_kept":13,"merged":[[0,0,1,0],[0,1,0,2]]}
["Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details) - shares","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive securities excluded from computation of earnings per share",{"v":14268788,"d":"14,268,788 "},{"v":12029204,"d":"12,029,204 "}]
["Unvested Restricted Stock Awards"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive securities excluded from computation of earnings per share"," ",{"v":27008,"d":"27,008 "}]
["Unvested Restricted Stock Units"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive securities excluded from computation of earnings per share",{"v":56250,"d":"56,250 "},{"v":103750,"d":"103,750 "}]
["Stock Options"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive securities excluded from computation of earnings per share",{"v":14212538,"d":"14,212,538 "},{"v":11898446,"d":"11,898,446 "}]

{"sheet":"Marketable Securities - Schedul","index":38,"n_rows":24,"n_cols":3,"rows_kept":24}
["Marketable Securities - Schedule of Marketable Securities (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Agency Securities"," "," "]
["Marketable Securities [Line Items]"," "," "]
["Marketable securities, Amortized cost"," ",{"v":10431,"d":"$ 10,431"}]
["Marketable securities, Gross unrealized gain"," ",{"v":19,"d":"19 "}]
["Marketable securities, Fair value"," ",{"v":10450,"d":"10,450 "}]
["Corporate Debt Securities"," "," "]
["Marketable Securities [Line Items]"," "," "]
["Marketable securities, Amortized cost",{"v":70059,"d":"$ 70,059"},{"v":67806,"d":"67,806 "}]
["Marketable securities, Gross unrealized gain",{"v":44,"d":"44 "},{"v":193,"d":"193 "}]
["Marketable securities, Gross unrealized loss",{"v":-27,"d":"(27)"},{"v":-20,"d":"(20)"}]
["Marketable securities, Fair value",{"v":70076,"d":"70,076 "},{"v":67979,"d":"67,979 "}]
["U.S. Government Securities"," "," "]
["Marketable Securities [Line Items]"," "," "]
["Marketable securities, Amortized cost",{"v":51046,"d":"51,046 "},{"v":129184,"d":"129,184 "}]
["Marketable securities, Gross unrealized gain",{"v":18,"d":"18 "},{"v":72,"d":"72 "}]
["Marketable securities, Gross unrealized loss"," ",{"v":-41,"d":"(41)"}]
["Marketable securities, Fair value",{"v":51064,"d":"51,064 "},{"v":129215,"d":"129,215 "}]
["Marketable Securities"," "," "]
["Marketable Securities [Line Items]"," "," "]
["Marketable securities, Amortized cost",{"v":121105,"d":"121,105 "},{"v":207421,"d":"207,421 "}]
["Marketable securities, Gross unrealized gain",{"v":62,"d":"62 "},{"v":284,"d":"284 "}]
["Marketable securities, Gross unrealized loss",{"v":-27,"d":"(27)"},{"v":-61,"d":"(61)"}]
["Marketable securities, Fair value",{"v":121140,"d":"$ 121,140"},{"v":207644,"d":"$ 207,644"}]

{"sheet":"Marketable Securities - Additio","index":39,"n_rows":4,"n_cols":2,"rows_kept":4}
["Marketable Securities - Additional Information (Details) $ in Millions","Dec. 31, 2024 USD ($) Security"]
["Investments, Debt and Equity Securities [Abstract]"," "]
["Number of marketable securities | Security",{"v":16,"d":"16 "}]
["Securities fair market value unrealized loss position | $",{"v":18.6,"d":"$ 18.6"}]

{"sheet":"Fair Value of Financial Instr_3","index":40,"n_rows":28,"n_cols":3,"rows_kept":28}
["Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Agency Securities"," "," "]
["Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"," "," "]
["Fair value measurement, assets"," ",{"v":10450,"d":"$ 10,450"}]
["Corporate Debt Securities"," "," "]
["Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"," "," "]
["Fair value measurement, assets",{"v":70076,"d":"$ 70,076"},{"v":67979,"d":"67,979 "}]
["U.S. Government Securities"," "," "]
["Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"," "," "]
["Fair value measurement, assets",{"v":51064,"d":"51,064 "},{"v":129215,"d":"129,215 "}]
["Recurring basis | Quoted Prices in Active Markets for Identical Assets (Level 1)"," "," "]
["Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"," "," "]
["Fair value measurement, assets",{"v":11246,"d":"11,246 "},{"v":24369,"d":"24,369 "}]
["Recurring basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds"," "," "]
["Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"," "," "]
["Fair value measurement, assets",{"v":11246,"d":"11,246 "},{"v":24369,"d":"24,369 "}]
["Recurring basis | Significant other observable inputs (Level 2)"," "," "]
["Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"," "," "]
["Fair value measurement, assets",{"v":121140,"d":"121,140 "},{"v":207644,"d":"207,644 "}]
["Recurring basis | Significant other observable inputs (Level 2) | Agency Securities"," "," "]
["Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"," "," "]
["Fair value measurement, assets"," ",{"v":10450,"d":"10,450 "}]
["Recurring basis | Significant other observable inputs (Level 2) | Corporate Debt Securities"," "," "]
["Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"," "," "]
["Fair value measurement, assets",{"v":70076,"d":"70,076 "},{"v":67979,"d":"67,979 "}]
["Recurring basis | Significant other observable inputs (Level 2) | U.S. Government Securities"," "," "]
["Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"," "," "]
["Fair value measurement, assets",{"v":51064,"d":"$ 51,064"},{"v":129215,"d":"$ 129,215"}]

{"sheet":"Property and Equipment - Schedu","index":41,"n_rows":20,"n_cols":3,"rows_kept":20}
["Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property, plant and equipment, gross",{"v":12025,"d":"$ 12,025"},{"v":10891,"d":"$ 10,891"}]
["Less accumulated depreciation",{"v":-5258,"d":"(5,258)"},{"v":-3566,"d":"(3,566)"}]
["Property and equipment, net",{"v":6767,"d":"6,767 "},{"v":7325,"d":"7,325 "}]
["Lab equipment"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property, plant and equipment, gross",{"v":7920,"d":"7,920 "},{"v":6643,"d":"6,643 "}]
["Leasehold improvements"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property, plant and equipment, gross",{"v":1700,"d":"1,700 "},{"v":1582,"d":"1,582 "}]
["IT equipment"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property, plant and equipment, gross",{"v":505,"d":"505 "},{"v":470,"d":"470 "}]
["Furniture and fixtures"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property, plant and equipment, gross",{"v":1900,"d":"1,900 "},{"v":1858,"d":"1,858 "}]
["Construction in progress"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property, plant and equipment, gross",{"v":0,"d":"$ 0"},{"v":338,"d":"$ 338"}]

{"sheet":"Accrued Expenses and Other Cu_3","index":42,"n_rows":6,"n_cols":3,"rows_kept":6}
["Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Payables and Accruals [Abstract]"," "," "]
["Compensation and related benefits",{"v":9022,"d":"$ 9,022"},{"v":9157,"d":"$ 9,157"}]
["Research and development",{"v":5416,"d":"5,416 "},{"v":5666,"d":"5,666 "}]
["Other",{"v":771,"d":"771 "},{"v":945,"d":"945 "}]
["Accrued expenses and other current liabilities",{"v":15209,"d":"$ 15,209"},{"v":15768,"d":"$ 15,768"}]

{"sheet":"Commitments - Additional Inform","index":43,"n_rows":49,"n_cols":5,"rows_kept":49,"merged":[[0,0,1,0],[0,3,0,4]]}
["Commitments - Additional Information (Details) $ in Thousands","1 Months Ended","3 Months Ended","12 Months Ended"]
[null,"May 31, 2024 USD ($)","Sep. 30, 2022 USD ($)","Dec. 31, 2024 USD ($) ft² Extension","Dec. 31, 2023 USD ($)"]
["Other Commitments [Line Items]"," "," "," "," "]
["Right-of-use asset"," "," ",{"v":28699,"d":"$ 28,699"},{"v":30412,"d":"$ 30,412"}]
["Lease liability"," "," ",{"v":17817,"d":"17,817 "}," "]
["Lease cost"," "," ",{"v":4400,"d":"4,400 "},{"v":2500,"d":"2,500 "}]
["Short-term lease cost"," "," ",{"v":200,"d":"200 "},{"v":200,"d":"200 "}]
["Cash paid in the measurement of operating lease liabilities"," "," ",{"v":1583,"d":"1,583 "},{"v":1928,"d":"1,928 "}]
["Reimbursements for development of lab space"," "," ",{"v":2400,"d":"$ 2,400"}," "]
["Reimbursements for development of lab space period"," "," ","3 years"," "]
["Reimbursements for development of lab space previous expiration year"," "," ","2023"," "]
["Reimbursements for development of lab space expiration year"," "," ","2026"," "]
["Additional grant for development of lab space"," ",{"v":1000,"d":"$ 1,000"}," "," "]
["Grant for development of lab space"," "," ",{"v":3400,"d":"$ 3,400"}," "]
["Disbursement incurred costs for lab space"," "," ",{"v":3400,"d":"3,400 "}," "]
["Other income related to grant"," "," ",{"v":200,"d":"$ 200"}," "]
["Defined contribution plan, maximum annual contributions per employee, percent"," "," ",{"v":1,"d":"100%"}," "]
["Defined contribution plan, employer matching contribution, percent of employee's gross pay"," "," ",{"v":0.03,"d":"3%"}," "]
["Defined contribution plan, employer discretionary contribution amount"," "," ",{"v":800,"d":"$ 800"},{"v":700,"d":"700 "}]
["Research and development"," "," ",{"v":117995,"d":"117,995 "},{"v":103393,"d":"103,393 "}]
["Maximum"," "," "," "," "]
["Other Commitments [Line Items]"," "," "," "," "]
["Approved grant receivable to increasing jobs"," "," ",{"v":3100,"d":"3,100 "}," "]
["License Agreement"," "," "," "," "]
["Other Commitments [Line Items]"," "," "," "," "]
["Transaction price",{"v":3000,"d":"$ 3,000"}," "," "," "]
["Deferred revenue recognized"," "," ",{"v":7000,"d":"$ 7,000"}," "]
["Upfront, non-refundable fee",{"v":3000,"d":"3,000 "}," "," "," "]
["Near term payment upon transfer of materials",{"v":4000,"d":"4,000 "}," "," "," "]
["License Agreement | Maximum"," "," "," "," "]
["Other Commitments [Line Items]"," "," "," "," "]
["Potential developmental milestones receivable",{"v":37000,"d":"37,000 "}," "," "," "]
["Potential sales milestone",{"v":100000,"d":"100,000 "}," "," "," "]
["API Transfer"," "," "," "," "]
["Other Commitments [Line Items]"," "," "," "," "]
["Transaction price",{"v":4000,"d":"$ 4,000"}," "," "," "]
["Chestnut Run Lease"," "," "," "," "]
["Other Commitments [Line Items]"," "," "," "," "]
["Lease renewal period"," "," ","5 years"," "]
["Operating lease estimated incremental borrowing rate percent"," "," ",{"v":0.15,"d":"15%"}," "]
["Area of lease premises | ft²"," "," ",{"v":81000,"d":"81,000 "}," "]
["Initial term of lease"," "," ","162 months"," "]
["Number of lease extensions | Extension"," "," ",{"v":3,"d":"3 "}," "]
["Chestnut Run Lease | Letter of Credit"," "," "," "," "]
["Other Commitments [Line Items]"," "," "," "," "]
["Security deposit"," "," ",{"v":4000,"d":"$ 4,000"},{"v":4000,"d":"$ 4,000"}]
["Chestnut Run Lease | Letter of Credit | Pro Forma"," "," "," "," "]
["Other Commitments [Line Items]"," "," "," "," "]
["Security deposit"," "," ",{"v":500,"d":"$ 500"}," "]

{"sheet":"Commitments - Schedule of Suppl","index":44,"n_rows":14,"n_cols":3,"rows_kept":14}
["Commitments - Schedule of Supplemental Balance Sheet and Other Information related to Operating and Finance Leases (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Lease Liability [Line Items]"," "," "]
["Operating",{"v":28699,"d":"$ 28,699"},{"v":30412,"d":"$ 30,412"}]
["Finance",{"v":523,"d":"$ 523"}," "]
["Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]","Property, Plant and Equipment, Net","Property, Plant and Equipment, Net"]
["Total leased assets",{"v":29222,"d":"$ 29,222"},{"v":30412,"d":"$ 30,412"}]
["Operating lease liability",{"v":2492,"d":"2,492 "},{"v":1481,"d":"1,481 "}]
["Finance lease liability",{"v":208,"d":"208 "}," "]
["Operating lease liability",{"v":15325,"d":"15,325 "},{"v":15407,"d":"15,407 "}]
["Total lease liabilities",{"v":18025,"d":"$ 18,025"},{"v":16888,"d":"$ 16,888"}]
["Weighted-average discount rate, Operating lease",{"v":0.15,"d":"15%"},{"v":0.15,"d":"15%"}]
["Weighted-average discount rate, Finance lease",{"v":0.105,"d":"10.50%"}," "]
["Weighted-average remaining lease term, Operating lease (years)","12 years 4 months 24 days","13 years 6 months"]
["Weighted-average remaining lease term, Finance lease (years)","3 months 18 days"," "]

{"sheet":"Commitments - Schedule of Sup_2","index":45,"n_rows":8,"n_cols":3,"rows_kept":8,"merged":[[0,0,1,0],[0,1,0,2]]}
["Commitments - Schedule of Supplemental Cash Flow Information related to leases (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Commitments and Contingencies Disclosure [Abstract]"," "," "]
["Operating cash flows from operating lease",{"v":1583,"d":"$ 1,583"},{"v":1928,"d":"$ 1,928"}]
["Operating cash flows from finance lease",{"v":30,"d":"30 "}," "]
["Financing cash flows from finance lease",{"v":395,"d":"395 "}," "]
["Operating lease right-of-use asset obtained in exchange for lease oblgations"," ",{"v":16680,"d":"$ 16,680"}]
["Finance lease right-of-use asset obtained in exchange for lease oblgations",{"v":603,"d":"$ 603"}," "]

{"sheet":"Commitments - Schedule of Futur","index":46,"n_rows":16,"n_cols":2,"rows_kept":16}
["Commitments - Schedule of Future Minimum Annual Lease Payments Under Operating and Finance Lease (Details) $ in Thousands","Dec. 31, 2024 USD ($)"]
["Lease Liability [Line Items]"," "]
["2025",{"v":2708,"d":"$ 2,708"}]
["2026",{"v":2973,"d":"2,973 "}]
["2027",{"v":3047,"d":"3,047 "}]
["2028",{"v":3124,"d":"3,124 "}]
["2029",{"v":3202,"d":"3,202 "}]
["Thereafter",{"v":26376,"d":"26,376 "}]
["Total undiscounted lease payments",{"v":41430,"d":"41,430 "}]
["Less imputed interest",{"v":-23613,"d":"(23,613)"}]
["Lease liability",{"v":17817,"d":"17,817 "}]
["Finance lease"," "]
["2025",{"v":213,"d":"213 "}]
["Total undiscounted lease payments",{"v":213,"d":"213 "}]
["Less imputed interest",{"v":-5,"d":"(5)"}]
["Lease liability",{"v":208,"d":"$ 208"}]

{"sheet":"Segments - Additional Informati","index":47,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Segments - Additional Information (Details)","12 Months Ended"]
[null,"Dec. 31, 2024 Segment"]
["Segment Reporting [Abstract]"," "]
["Number of operating segments",{"v":1,"d":"1 "}]

{"sheet":"Segments - Schedule of Signific","index":48,"n_rows":29,"n_cols":3,"rows_kept":29,"merged":[[0,0,1,0],[0,1,0,2]]}
["Segments - Schedule of Significant Expense Categories Reviewed by CODM (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Segment Reporting Information [Line Items]"," "," "]
["Revenue from license agreement",{"v":7000,"d":"$ 7,000"}," "]
["Operating expenses:"," "," "]
["Research and development",{"v":117995,"d":"117,995 "},{"v":103393,"d":"$ 103,393"}]
["General and administrative",{"v":28719,"d":"28,719 "},{"v":28884,"d":"28,884 "}]
["Total operating expenses",{"v":146714,"d":"146,714 "},{"v":132277,"d":"132,277 "}]
["Loss from operations",{"v":-139714,"d":"(139,714)"},{"v":-132277,"d":"(132,277)"}]
["Other income, net",{"v":12541,"d":"12,541 "},{"v":10445,"d":"10,445 "}]
["Net loss",{"v":-127173,"d":"(127,173)"},{"v":-121832,"d":"(121,832)"}]
["PRT3789"," "," "]
["Operating expenses:"," "," "]
["Research and development",{"v":20173,"d":"20,173 "},{"v":9738,"d":"9,738 "}]
["PRT2527"," "," "]
["Operating expenses:"," "," "]
["Research and development",{"v":11594,"d":"11,594 "},{"v":7573,"d":"7,573 "}]
["PRT7732"," "," "]
["Operating expenses:"," "," "]
["Research and development",{"v":9195,"d":"9,195 "}," "]
["Discovery Programs"," "," "]
["Operating expenses:"," "," "]
["Research and development",{"v":13856,"d":"13,856 "},{"v":12387,"d":"12,387 "}]
["Other"," "," "]
["Operating expenses:"," "," "]
["Research and development",{"v":1346,"d":"1,346 "},{"v":12922,"d":"12,922 "}]
["General Costs, Including Personnel Related"," "," "]
["Operating expenses:"," "," "]
["Research and development",{"v":61831,"d":"$ 61,831"},{"v":60773,"d":"$ 60,773"}]

{"sheet":"Common Stock - Additional Infor","index":49,"n_rows":50,"n_cols":7,"rows_kept":50,"merged":[[0,0,1,0],[0,2,0,3],[0,4,0,5]]}
["Common Stock - Additional Information (Details) - USD ($)","1 Months Ended","3 Months Ended",null,"12 Months Ended"]
[null,"Mar. 31, 2023","Dec. 31, 2023","Jun. 30, 2023","Dec. 31, 2024","Dec. 31, 2023","May 01, 2024"]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Gross proceeds from issuance of common stock and prefunded warrants"," "," ",{"v":113000000,"d":"$ 113,000,000"}," "," "," "]
["Offering costs"," ",{"v":200000,"d":"$ 200,000"},{"v":2600000,"d":"2,600,000 "}," ",{"v":200000,"d":"$ 200,000"}," "]
["Offering costs previously paid and deferred"," "," ",{"v":300000,"d":"300,000 "}," "," "," "]
["Net proceeds from issuance"," ",{"v":24800000,"d":"$ 24,800,000"},{"v":110400000,"d":"$ 110,400,000"}," "," "," "]
["2024 Shelf Registration"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Maximum aggregate offering amount"," "," "," "," "," ",{"v":400000000,"d":"$ 400,000,000"}]
["Shelf registration statement remaining amount"," "," "," ",{"v":400000000,"d":"$ 400,000,000"}," "," "]
["Open Market Sales Agreement | Jefferies LLC"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Percentage of commission on gross proceeds from sale of common stock",{"v":0.03,"d":"3%"}," "," "," "," "," "]
["Amount remaining under the sales agreement"," "," "," ",{"v":75000000,"d":"$ 75,000,000"}," "," "]
["Maximum | Open Market Sales Agreement | Jefferies LLC"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Common stock aggregate offering amount",{"v":75000000,"d":"$ 75,000,000"}," "," "," "," "," "]
["Pre-Funded Warrants"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Warrants exercise price per share"," ",{"v":0.0001,"d":"$ 0.0001"}," "," ",{"v":0.0001,"d":"$ 0.0001"}," "]
["Warrants exercised"," "," "," ",{"v":0,"d":"0 "}," "," "]
["Pre-Funded Warrants | Voting Common Stock"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Shares issued price per share"," "," ",{"v":5.7499,"d":"$ 5.7499"}," "," "," "]
["Warrants to purchase common stock"," "," ",{"v":12895256,"d":"12,895,256 "}," "," "," "]
["Pre-Funded Warrants | Voting Common Stock | Private Placement"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Shares issued price per share"," ",{"v":3.1499,"d":"$ 3.1499"}," "," ",{"v":3.1499,"d":"$ 3.1499"}," "]
["Warrants to purchase common stock"," ",{"v":7936759,"d":"7,936,759 "}," "," ",{"v":7936759,"d":"7,936,759 "}," "]
["Common Stock"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Common stock, voting rights"," "," "," ","The holders of the voting common stock are entitled to one vote for each share of voting common stock held at all meetings of stockholders"," "," "]
["Number of shares sold"," "," ",{"v":6761200,"d":"6,761,200 "}," "," "," "]
["Shares issued price per share"," "," ",{"v":5.75,"d":"$ 5.75"}," "," "," "]
["Common Stock | Minimum"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Beneficial ownership percentage"," "," "," ",{"v":0.0999,"d":"9.99%"}," "," "]
["Common Stock | Maximum"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Beneficial ownership percentage"," "," "," ",{"v":0.1999,"d":"19.99%"}," "," "]
["Common Stock | Voting Common Stock"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Number of shares sold"," "," ",{"v":5312978,"d":"5,312,978 "}," "," "," "]
["Shares issued during period"," "," "," "," ",{"v":5312978,"d":"5,312,978 "}," "]
["Shares purchased by underwriters"," "," ",{"v":2264456,"d":"2,264,456 "}," "," "," "]
["Common Stock | Non-voting Common Stock"," "," "," "," "," "," "]
["Class Of Stock [Line Items]"," "," "," "," "," "," "]
["Number of shares sold"," "," ",{"v":1448222,"d":"1,448,222 "}," "," "," "]
["Shares issued during period"," "," "," "," ",{"v":1448222,"d":"1,448,222 "}," "]

{"sheet":"Stock-Based Compensation - Addi","index":50,"n_rows":66,"n_cols":5,"rows_kept":66,"merged":[[0,0,1,0],[0,1,0,2]]}
["Stock-Based Compensation - Additional Information (Details)","12 Months Ended"]
[null,"Dec. 31, 2024 USD ($) Plan $ / shares shares","Dec. 31, 2023 USD ($) $ / shares","Jan. 01, 2025 shares","Dec. 31, 2020 shares"]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Number of equity incentive plans | Plan",{"v":2,"d":"2 "}," "," "," "]
["Aggregate intrinsic value of outstanding options",{"v":100000,"d":"$ 100,000"}," "," "," "]
["Aggregate intrinsic value of exercisable options",{"v":0,"d":"0 "}," "," "," "]
["Stock-based compensation expense",{"v":21345000,"d":"$ 21,345,000"},{"v":25616000,"d":"$ 25,616,000"}," "," "]
["Employee Stock Option"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Weighted-average grant date fair value of options granted | $ / shares",{"v":3.25,"d":"$ 3.25"},{"v":4.87,"d":"$ 4.87"}," "," "]
["Aggregate intrinsic value of options exercised",{"v":20000,"d":"$ 20,000"},{"v":100000,"d":"$ 100,000"}," "," "]
["Stock-based compensation expense",{"v":20800000,"d":"20,800,000 "},{"v":24600000,"d":"24,600,000 "}," "," "]
["Total unrecognized compensation expense related to unvested stock option awards",{"v":21900000,"d":"$ 21,900,000"}," "," "," "]
["Total unrecognized compensation expense, weighted-average period","2 years 14 days"," "," "," "]
["Restricted Stock Awards"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Award vesting period","4 years"," "," "," "]
["Stock-based compensation expense",{"v":100000,"d":"$ 100,000"},{"v":500000,"d":"500,000 "}," "," "]
["Restricted Stock Units"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Award vesting period","4 years"," "," "," "]
["Stock-based compensation expense",{"v":300000,"d":"$ 300,000"},{"v":300000,"d":"300,000 "}," "," "]
["Total unrecognized compensation expense, weighted-average period","1 year 3 months"," "," "," "]
["Share-based payment arrangement, nonvested award, unrecognized expense",{"v":200000,"d":"$ 200,000"}," "," "," "]
["2020 Equity Incentive Plan"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Number of shares authorized | shares"," "," "," ",{"v":4680000,"d":"4,680,000 "}]
["Number of shares available for future grants | shares",{"v":5417370,"d":"5,417,370 "}," "," "," "]
["Share authorization terms of award","The total number of shares initially authorized under the Plan was 4,680,000, which was increased on January 1, 2021 and will automatically increase on January 1st of each year, continuing for ten years, in an amount equal to five percent of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year."," "," "," "]
["Award term","10 years"," "," "," "]
["Share increase term","10 years"," "," "," "]
["Percentage of shares outstanding used to calculate annual increase in number of shares that can be issued",{"v":0.05,"d":"5%"}," "," "," "]
["2020 Equity Incentive Plan | Maximum"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Award vesting period","4 years"," "," "," "]
["2020 Equity Incentive Plan | Minimum"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Award vesting period","1 year"," "," "," "]
["2020 Employee Stock Purchase Plan"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Number of shares available for future grants | shares",{"v":1975570,"d":"1,975,570 "}," "," "," "]
["Share authorization terms of award","The number of shares of the Company’s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January 1st of each year and continuing for ten years beginning in 2021, in an amount equal to one percent of the total number of shares of all classes of the Company’s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year."," "," "," "]
["Share increase term","10 years"," "," "," "]
["Percentage of shares outstanding used to calculate annual increase in number of shares that can be issued",{"v":0.01,"d":"1%"}," "," "," "]
["Stock-based compensation expense",{"v":200000,"d":"$ 200,000"},{"v":300000,"d":"$ 300,000"}," "," "]
["Shares issued | shares",{"v":192864,"d":"192,864 "}," "," "," "]
["Eligible employees purchase common stock percentage of lower of fair market value",{"v":0.85,"d":"85%"}," "," "," "]
["Participants accrue rights to purchase maximum common stock amount",{"v":25000,"d":"$ 25,000"}," "," "," "]
["2020 Employee Stock Purchase Plan | Maximum"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Eligible employees contribution percentage",{"v":0.15,"d":"15%"}," "," "," "]
["Vesting After One Year | Restricted Stock Awards"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Percentage of stock options vested",{"v":0.25,"d":"25%"}," "," "," "]
["Vesting After One Year | Restricted Stock Units"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Percentage of stock options vested",{"v":0.25,"d":"25%"}," "," "," "]
["Vesting After One Year | 2020 Equity Incentive Plan"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Percentage of stock options vested",{"v":0.25,"d":"25%"}," "," "," "]
["Subsequent Event | 2020 Equity Incentive Plan"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Number of shares authorized | shares"," "," ",{"v":2757455,"d":"2,757,455 "}," "]
["Subsequent Event | 2020 Employee Stock Purchase Plan"," "," "," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "," "," "]
["Common stock additional capital shares reserved for future issuance | shares"," "," ",{"v":551491,"d":"551,491 "}," "]

{"sheet":"Stock-Based Compensation - Sche","index":51,"n_rows":10,"n_cols":3,"rows_kept":10,"merged":[[0,0,1,0],[0,1,0,2]]}
["Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "]
["Stock-based compensation expense",{"v":21345,"d":"$ 21,345"},{"v":25616,"d":"$ 25,616"}]
["Research and Development"," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "]
["Stock-based compensation expense",{"v":12134,"d":"12,134 "},{"v":12626,"d":"12,626 "}]
["General and Administrative"," "," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "]
["Stock-based compensation expense",{"v":9211,"d":"$ 9,211"},{"v":12990,"d":"$ 12,990"}]

{"sheet":"Stock-Based Compensation - Summ","index":52,"n_rows":17,"n_cols":4,"rows_kept":17,"merged":[[0,0,1,0],[0,1,0,3]]}
["Stock-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Share-Based Payment Arrangement [Abstract]"," "," "," "]
["Number of shares, Outstanding at beginning of period",{"v":11898446,"d":"11,898,446 "},{"v":9390930,"d":"9,390,930 "}," "]
["Number of shares, Granted",{"v":3922800,"d":"3,922,800 "},{"v":3238898,"d":"3,238,898 "}," "]
["Number of shares, Exercised",{"v":-14955,"d":"(14,955)"},{"v":-26899,"d":"(26,899)"}," "]
["Number of shares, Forfeited",{"v":-1593753,"d":"(1,593,753)"},{"v":-704483,"d":"(704,483)"}," "]
["Number of shares, Outstanding at end of period",{"v":14212538,"d":"14,212,538 "},{"v":11898446,"d":"11,898,446 "},{"v":9390930,"d":"9,390,930 "}]
["Number of shares, Exercisable at December 31, 2024",{"v":8518940,"d":"8,518,940 "}," "," "]
["Weighted average exercise price per share, Outstanding at beginning of period",{"v":10.6,"d":"$ 10.6"},{"v":12.08,"d":"$ 12.08"}," "]
["Weighted average exercise price per share, Granted",4.4,6.68," "]
["Weighted average exercise price per share, Exercised",3.98,1.78," "]
["Weighted average exercise price per share, Forfeited",9.09,12.58," "]
["Weighted average exercise price per share, Outstanding at end of period",9.07,{"v":10.6,"d":"$ 10.6"},{"v":12.08,"d":"$ 12.08"}]
["Weighted average exercise price per share, Exercisable at December 31, 2024",{"v":11.09,"d":"$ 11.09"}," "," "]
["Weighted average remaining contractual term (years), Outstanding","7 years 3 months 18 days","7 years 9 months 7 days","8 years 3 months 21 days"]
["Weighted average remaining contractual term (years), Exercisable","6 years 4 months 24 days"," "," "]

{"sheet":"Stock-Based Compensation - Su_2","index":53,"n_rows":41,"n_cols":2,"rows_kept":41,"merged":[[0,0,1,0]]}
["Stock-Based Compensation - Summary of Information about Stock Options Outstanding and Exercisable (Details)","12 Months Ended"]
[null,"Dec. 31, 2024 $ / shares shares"]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "]
["Options Outstanding, Number | shares",{"v":14212538,"d":"14,212,538 "}]
["Options Exercisable, Number Exercisable | shares",{"v":8518940,"d":"8,518,940 "}]
["$0.31 - $4.56"," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "]
["Range of Exercise Prices, Minimum",{"v":0.31,"d":"$ 0.31"}]
["Range of Exercise Prices, Maximum",{"v":4.56,"d":"$ 4.56"}]
["Options Outstanding, Number | shares",{"v":2991916,"d":"2,991,916 "}]
["Options Outstanding, Weighted Average Remaining Contractual Life (in years)","6 years 3 months 14 days"]
["Options Outstanding, Weighted Average Exercise Price",{"v":2.44,"d":"$ 2.44"}]
["Options Exercisable, Number Exercisable | shares",{"v":2051205,"d":"2,051,205 "}]
["Options Exercisable, Weighted Average Exercise Price",{"v":1.91,"d":"$ 1.91"}]
["$4.57 - $5.43"," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "]
["Range of Exercise Prices, Minimum",4.57]
["Range of Exercise Prices, Maximum",{"v":5.43,"d":"$ 5.43"}]
["Options Outstanding, Number | shares",{"v":3741327,"d":"3,741,327 "}]
["Options Outstanding, Weighted Average Remaining Contractual Life (in years)","8 years 7 months 24 days"]
["Options Outstanding, Weighted Average Exercise Price",{"v":4.69,"d":"$ 4.69"}]
["Options Exercisable, Number Exercisable | shares",{"v":841091,"d":"841,091 "}]
["Options Exercisable, Weighted Average Exercise Price",{"v":4.89,"d":"$ 4.89"}]
["$5.44 - $11.72"," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "]
["Range of Exercise Prices, Minimum",5.44]
["Range of Exercise Prices, Maximum",{"v":11.72,"d":"$ 11.72"}]
["Options Outstanding, Number | shares",{"v":4088593,"d":"4,088,593 "}]
["Options Outstanding, Weighted Average Remaining Contractual Life (in years)","7 years 9 months 25 days"]
["Options Outstanding, Weighted Average Exercise Price",{"v":7.86,"d":"$ 7.86"}]
["Options Exercisable, Number Exercisable | shares",{"v":2404123,"d":"2,404,123 "}]
["Options Exercisable, Weighted Average Exercise Price",{"v":8.13,"d":"$ 8.13"}]
["$11.73 - $88.98"," "]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "]
["Range of Exercise Prices, Minimum",11.73]
["Range of Exercise Prices, Maximum",{"v":88.98,"d":"$ 88.98"}]
["Options Outstanding, Number | shares",{"v":3390702,"d":"3,390,702 "}]
["Options Outstanding, Weighted Average Remaining Contractual Life (in years)","6 years 1 month 2 days"]
["Options Outstanding, Weighted Average Exercise Price",{"v":21.2,"d":"$ 21.20"}]
["Options Exercisable, Number Exercisable | shares",{"v":3222521,"d":"3,222,521 "}]
["Options Exercisable, Weighted Average Exercise Price",{"v":20.75,"d":"$ 20.75"}]

{"sheet":"Stock-Based Compensation - Sc_2","index":54,"n_rows":6,"n_cols":3,"rows_kept":6,"merged":[[0,0,1,0],[0,1,0,2]]}
["Stock-Based Compensation - Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions (Details) - Stock Options","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "]
["Expected volatility",{"v":0.8496,"d":"84.96%"},{"v":0.8357,"d":"83.57%"}]
["Risk-free interest rate",{"v":0.0419,"d":"4.19%"},{"v":0.0382,"d":"3.82%"}]
["Expected life (in years)","6 years 18 days","6 years 7 days"]

{"sheet":"Stock-Based Compensation - Su_3","index":55,"n_rows":9,"n_cols":3,"rows_kept":9,"merged":[[0,0,1,0],[0,1,0,2]]}
["Stock-Based Compensation - Summary of Activity related to RSA Stock-Based Payment Awards (Details) - Restricted Stock Awards - $ / shares","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "]
["Number of shares, Unvested balance at beginning of period",{"v":27008,"d":"27,008 "},{"v":201716,"d":"201,716 "}]
["Number of shares, Vested",{"v":-27008,"d":"(27,008)"},{"v":-174708,"d":"(174,708)"}]
["Number of shares, Unvested balance at end of period"," ",{"v":27008,"d":"27,008 "}]
["Weighted-average grant date fair value, Unvested balance at beginning of period",{"v":3.26,"d":"$ 3.26"},{"v":2.81,"d":"$ 2.81"}]
["Weighted-average grant date fair value, Vested",{"v":3.26,"d":"$ 3.26"},2.74]
["Weighted-average grant date fair value, Unvested balance at end of period"," ",{"v":3.26,"d":"$ 3.26"}]

{"sheet":"Stock-Based Compensation - Su_4","index":56,"n_rows":11,"n_cols":3,"rows_kept":11,"merged":[[0,0,1,0],[0,1,0,2]]}
["Stock-Based Compensation - Summary of Activity related to RSU Stock-Based Payment Awards (Details) - Restricted Stock Units - $ / shares","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"," "," "]
["Number of shares, Unvested balance at beginning of period",{"v":103750,"d":"103,750 "},{"v":165000,"d":"165,000 "}]
["Number of shares, Vested",{"v":-42500,"d":"(42,500)"},{"v":-61250,"d":"(61,250)"}]
["Number of shares, Forfeited",{"v":-5000,"d":"(5,000)"}," "]
["Number of shares, Unvested balance at end of period",{"v":56250,"d":"56,250 "},{"v":103750,"d":"103,750 "}]
["Weighted-average grant date fair value, Unvested balance at beginning of period",{"v":6.16,"d":"$ 6.16"},{"v":6.08,"d":"$ 6.08"}]
["Weighted-average grant date fair value, Vested",6.44,5.96]
["Weighted-average grant date fair value, Forfeited",18.32," "]
["Weighted-average grant date fair value, Unvested balance at end of period",{"v":4.86,"d":"$ 4.86"},{"v":6.16,"d":"$ 6.16"}]

{"sheet":"Income Taxes - Schedule of Defe","index":57,"n_rows":16,"n_cols":3,"rows_kept":16}
["Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Deferred tax assets:"," "," "]
["Net operating loss carryforwards",{"v":81520,"d":"$ 81,520"},{"v":71963,"d":"$ 71,963"}]
["Research and development credits",{"v":23668,"d":"23,668 "},{"v":20555,"d":"20,555 "}]
["Research and development capitalization",{"v":59341,"d":"59,341 "},{"v":39867,"d":"39,867 "}]
["Stock-based compensation",{"v":15312,"d":"15,312 "},{"v":12990,"d":"12,990 "}]
["Accrued expense",{"v":2783,"d":"2,783 "},{"v":2539,"d":"2,539 "}]
["Lease liabilities",{"v":5033,"d":"5,033 "},{"v":4715,"d":"4,715 "}]
["Gross deferred tax assets",{"v":187657,"d":"187,657 "},{"v":152629,"d":"152,629 "}]
["Less: valuation allowance",{"v":-182642,"d":"(182,642)"},{"v":-147616,"d":"(147,616)"}]
["Total deferred tax asset",{"v":5015,"d":"5,015 "},{"v":5013,"d":"5,013 "}]
["Deferred tax liability"," "," "]
["Right-of-use assets",{"v":-4595,"d":"(4,595)"},{"v":-4641,"d":"(4,641)"}]
["Depreciation",{"v":-420,"d":"(420)"},{"v":-372,"d":"(372)"}]
["Total deferred tax liabilities",{"v":-5015,"d":"(5,015)"},{"v":-5013,"d":"(5,013)"}]
["Net deferred tax assets",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}]

{"sheet":"Income Taxes - Additional Infor","index":58,"n_rows":31,"n_cols":3,"rows_kept":31,"merged":[[0,0,1,0],[0,1,0,2]]}
["Income Taxes - Additional Information (Details) - USD ($)","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Income Tax Disclosure [Line Items]"," "," "]
["Deferred tax assets, valuation allowance increase",{"v":35000000,"d":"$ 35,000,000"},{"v":36600000,"d":"$ 36,600,000"}]
["Research and development tax credits",{"v":23668000,"d":"23,668,000 "},{"v":20555000,"d":"20,555,000 "}]
["Deferred tax assets, capitalized research and development expense",{"v":59341000,"d":"$ 59,341,000"},{"v":39867000,"d":"$ 39,867,000"}]
["NOL and tax credit carryforwards","The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions."," "]
["Accrued interest related to uncertain tax positions",{"v":0,"d":"$ 0"}," "]
["Accrued penalties related to uncertain tax positions",{"v":0,"d":"0 "}," "]
["Interest related to uncertain tax positions",{"v":0,"d":"0 "}," "]
["Penalties related to uncertain tax positions",{"v":0,"d":"$ 0"}," "]
["Non-U.S. Based"," "," "]
["Income Tax Disclosure [Line Items]"," "," "]
["Taxpayers required period to capitalize and amortize research development expense","15 years"," "]
["U.S. Based"," "," "]
["Income Tax Disclosure [Line Items]"," "," "]
["Taxpayers required period to capitalize and amortize research development expense","5 years"," "]
["Tennessee"," "," "]
["Income Tax Disclosure [Line Items]"," "," "]
["NOL carryforwards expiration year","2037"," "]
["Massachusetts"," "," "]
["Income Tax Disclosure [Line Items]"," "," "]
["NOL carryforwards expiration year","2042"," "]
["Internal Revenue Service (IRS)"," "," "]
["Income Tax Disclosure [Line Items]"," "," "]
["Research and development tax credits",{"v":23600000,"d":"$ 23,600,000"}," "]
["Tax credits expiration year","2039"," "]
["Delaware"," "," "]
["Income Tax Disclosure [Line Items]"," "," "]
["Research and development tax credits",{"v":43000,"d":"$ 43,000"}," "]
["Tax credits expiration year","2031"," "]

{"sheet":"Income Taxes - Schedule of Reco","index":59,"n_rows":11,"n_cols":3,"rows_kept":11,"merged":[[0,0,1,0],[0,1,0,2]]}
["Income Taxes - Schedule of Reconciliation of the Federal Income tax Rate to Effective Tax Rate (Details)","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Effective Income Tax Rate Reconciliation, Percent [Abstract]"," "," "]
["Federal tax benefit at statutory rate","(21.00%)","(21.00%)"]
["State tax, net of federal benefit","(6.60%)","(6.60%)"]
["Permanent differences",{"v":0.01,"d":"1%"},{"v":0.011,"d":"1.10%"}]
["Research and development","(2.40%)","(4.40%)"]
["Change in valuation allowance",{"v":0.275,"d":"27.50%"},{"v":0.3,"d":"30%"}]
["Share-based compensation",{"v":0.015,"d":"1.50%"},{"v":0.009,"d":"0.90%"}]
["Other",{"v":0,"d":"0%"},{"v":0,"d":"0%"}]
["Effective tax rate",{"v":0,"d":"0%"},{"v":0,"d":"0%"}]

{"sheet":"Income Taxes - Schedule of Fede","index":60,"n_rows":11,"n_cols":3,"rows_kept":11}
["Income Taxes - Schedule of Federal and State Net Operating Losses and Research Tax Credits (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Operating Loss Carryforwards [Line Items]"," "," "]
["NOL carryforwards",{"v":81520,"d":"$ 81,520"},{"v":71963,"d":"$ 71,963"}]
["Federal"," "," "]
["Operating Loss Carryforwards [Line Items]"," "," "]
["NOL carryforwards",{"v":292193,"d":"292,193 "},{"v":257976,"d":"257,976 "}]
["Research tax credits",{"v":23634,"d":"23,634 "},{"v":20521,"d":"20,521 "}]
["State"," "," "]
["Operating Loss Carryforwards [Line Items]"," "," "]
["NOL carryforwards",{"v":293621,"d":"293,621 "},{"v":259051,"d":"259,051 "}]
["Research tax credits",{"v":43,"d":"$ 43"},{"v":43,"d":"$ 43"}]